ArticlePDF Available

Alcohol use and burden for 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016

Authors:

Abstract and Figures

BACKGROUND: Alcohol use is a leading risk factor for death and disability, but its overall association with health remains complex given the possible protective effects of moderate alcohol consumption on some conditions. With our comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of 15 years and 95 years and older. METHODS: Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking, abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g of pure ethyl alcohol), and alcohol-attributable deaths and DALYs. We made several methodological improvements compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the overall risk to individual health. FINDINGS: Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016, accounting for 2·2% (95% uncertainty interval [UI] 1·5–3·0) of age-standardised female deaths and 6·8% (5·8–8·0) of age-standardised male deaths. Among the population aged 15–49 years, alcohol use was the leading risk factor globally in 2016, with 3·8% (95% UI 3·2–4·3) of female deaths and 12·2% (10·8–13·6) of male deaths attributable to alcohol use. For the population aged 15–49 years, female attributable DALYs were 2·3% (95% UI 2·0–2·6) and male attributable DALYs were 8·9% (7·8–9·9). The three leading causes of attributable deaths in this age group were tuberculosis (1·4% [95% UI 1·0–1·7] of total deaths), road injuries (1·2% [0·7–1·9]), and self-harm (1·1% [0·6–1·5]). For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27·1% (95% UI 21·2–33·3) of total alcohol-attributable female deaths and 18·9% (15·3–22·6) of male deaths. The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0·0–0·8) standard drinks per week. INTERPRETATION: Alcohol use is a leading risk factor for global disease burden and causes substantial health loss. We found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and the level of consumption that minimises health loss is zero. These results suggest that alcohol control policies might need to be revised worldwide, refocusing on efforts to lower overall population-level consumption. FUNDING: Bill & Melinda Gates Foundation.
Content may be subject to copyright.
Articles
www.thelancet.com Vol 392 September 22, 2018
1015
Alcohol use and burden for 195 countries and territories,
1990–2016: a systematic analysis for the Global Burden of
Disease Study 2016
GBD 2016 Alcohol Collaborators*
Summary
Background Alcohol use is a leading risk factor for death and disability, but its overall association with health remains
complex given the possible protective eects of moderate alcohol consumption on some conditions. With our
comprehensive approach to health accounting within the Global Burden of Diseases, Injuries, and Risk Factors Study
2016, we generated improved estimates of alcohol use and alcohol-attributable deaths and disability-adjusted life-
years (DALYs) for 195 locations from 1990 to 2016, for both sexes and for 5-year age groups between the ages of
15 years and 95 years and older.
Methods Using 694 data sources of individual and population-level alcohol consumption, along with 592 prospective
and retrospective studies on the risk of alcohol use, we produced estimates of the prevalence of current drinking,
abstention, the distribution of alcohol consumption among current drinkers in standard drinks daily (defined as 10 g
of pure ethyl alcohol), and alcohol-attributable deaths and DALYs. We made several methodological improvements
compared with previous estimates: first, we adjusted alcohol sales estimates to take into account tourist and
unrecorded consumption; second, we did a new meta-analysis of relative risks for 23 health outcomes associated with
alcohol use; and third, we developed a new method to quantify the level of alcohol consumption that minimises the
overall risk to individual health.
Findings Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016, accounting for
2·2% (95% uncertainty interval [UI] 1·5–3·0) of age-standardised female deaths and 6·8% (5·8–8·0) of age-
standardised male deaths. Among the population aged 15–49 years, alcohol use was the leading risk factor globally in
2016, with 3·8% (95% UI 3·2–4·3) of female deaths and 12·2% (10·8–13·6) of male deaths attributable to alcohol
use. For the population aged 15–49 years, female attributable DALYs were 2·3% (95% UI 2·0–2·6) and male
attributable DALYs were 8·9% (7·8–9·9). The three leading causes of attributable deaths in this age group were
tuberculosis (1·4% [95% UI 1·0–1·7] of total deaths), road injuries (1·2% [0·7–1·9]), and self-harm (1·1% [0·6–1·5]).
For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths
in 2016, constituting 27·1% (95% UI 21·2–33·3) of total alcohol-attributable female deaths and 18·9% (15·3–22·6) of
male deaths. The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0·0–0·8)
standard drinks per week.
Interpretation Alcohol use is a leading risk factor for global disease burden and causes substantial health loss. We
found that the risk of all-cause mortality, and of cancers specifically, rises with increasing levels of consumption, and
the level of consumption that minimises health loss is zero. These results suggest that alcohol control policies might
need to be revised worldwide, refocusing on eorts to lower overall population-level consumption.
Funding Bill & Melinda Gates Foundation.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Alcohol use has a complex association with health.
Researchers have recognised alcohol use as a leading risk
factor for disease burden, and studies link its consumption
to 60 acute and chronic diseases.1–3 Additionally, some
research suggests that low levels of alcohol consumption
can have a protective eect on ischaemic heart disease,
diabetes, and several other outcomes.4–6 This finding
remains an open question, and recent studies have
challenged this view by use of mendelian randomisation
and meta-analyses.7–10
Determination of harm due to alcohol use is com-
plicated further by the multiple mechanisms through
which alcohol use aects health: through cumulative
consumption leading to adverse eects on organs and
tissues; by acute intoxication leading to injuries or
poisoning; and by dependent drinking leading to
impairments and potentially self-harm or violence. These
eects are also influenced by an individual’s consumption
volume and pattern of drinking.2 Measuring the health
eects of alcohol use requires careful consideration of all
these factors.
Lancet 2018; 392: 1015–35
Published Online
August 23, 2018
http://dx.doi.org/10.1016/
S0140-6736(18)31310-2
See Comment page 987
*Collaborators listed at the end
of the Article
Correspondence to:
Prof Emmanuela Gakidou,
Institute for Health Metrics and
Evaluation, University of
Washington, Seattle, WA 98121,
USA
gakidou@uw.edu
Articles
1016
www.thelancet.com Vol 392 September 22, 2018
Several studies have attempted to address these factors
to provide global estimates of alcohol consumption and
its associated health eects. The most comprehensive
among these studies have been WHO’s Global Status
Report on Alcohol and Health, as well as previous
iterations of the Global Burden of Diseases, Injuries, and
Risk Factors Study (GBD).11–13 The present study aims to
build upon pre-existing work and to address several
limitations found in earlier research.
First, the available studies have assessed the risk of
alcohol use by relying on external meta-analyses, which
do not control for confounding in the selection of
the reference category within constituent studies. This
approach is problematic because of the so-called sick
quitter hypothesis, which emphasises the importance of
reference category selection in correctly assessing risk
among drinkers, along with other confounding study
characteristics such as survival bias.8,14–17 Until recently,
most meta-analyses of alcohol consumption have not
controlled for the composition of the reference category.
Subsequently, assessments of harm relying on these
studies have been biased. We sought to resolve this issue
within our meta-analyses by including controls for
dierent reference categories and the average age of
participants.
Second, previous studies have used sales data to estimate
population-level alcohol stock. Researchers have noted the
benefit of using sales data instead of survey data for
quantifying alcohol stock available within a location.18,19
However, sales data still have bias because of consumption
by tourists and unrecorded consumption from illicit sales,
home brewing, and local beverages. Without correction for
these factors, estimates relying on sales data can be biased
and lead to inaccurate cross-national comparisons. In the
current study, we adjusted the estimates of population-
level alcohol stock to account for the eects of tourism and
unrecorded consumption.
Third, previous studies have assumed zero as the
counterfactual exposure level that minimises harm. Within
a comparative risk assessment approach, a counterfactual
level of consumption that minimises harm is required
to estimate population attributable fractions (PAFs).1
However, this counterfactual level needs to be estimated,
rather than assumed, given the complexities involved in
estimating the risk of alcohol use across outcomes. Relying
on this assumption can fail to capture any potential non-
linear eects between alcohol use and health. Our study
proposes a new method for the use of available evidence to
establish a counterfactual level of exposure across varied
relative risks, which provides tangible evidence for low-risk
drinking recommendations.
In the present study, we aimed to address these limita-
tions and provide the best available estimates of alcohol
use and the associated health burden. We estimated the
Research in context
Evidence before this study
Although researchers recognise alcohol use as a leading risk
factor for premature death and disability, some evidence
suggests that low intake might have a protective effect on
specific conditions such as ischaemic heart disease and diabetes.
Monitoring of consumption behaviour is required to analyse the
health effects of alcohol use. Historically, researchers have relied
on self-reported survey data to estimate consumption levels
and trends. However, these data have systematic biases that
make cross-country comparisons unreliable. The Global Status
Report on Alcohol and Health, as well as previous iterations of
the Global Burden of Diseases, Injuries, and Risk Factors Study,
have sought to produce harmonised, cross-country comparisons
of alcohol consumption and its harms, by leveraging data on
alcohol sales, the prevalence of current drinking and abstention,
and self-reports of consumption amounts.
Added value of this study
In this analysis we improved available estimates of alcohol use and
its associated health burden in five ways. First, we consolidated
694 individual and population-level data sources to estimate
alcohol consumption levels among current drinkers. Second, we
developed a method to adjust population-level consumption for
alcohol consumed by tourists. Third, we improved pre-existing
methods that account for unrecorded population-level
consumption. Fourth, we did a new systematic review and
meta-analysis of alcohol use and 23 associated health outcomes,
which we used to estimate new dose–response curves of relative
risk. Fifth, using the new relative risk curves and a new analytical
method, we estimated the exposure of alcohol consumption
that minimises an individual’s total attributable risk.
Implications of all the available evidence
The total attributable burden of alcohol use was larger than
previous evidence has indicated and increases monotonically
with consumption. Based on weighted relative risk curves for
each health outcome associated with alcohol use, the level of
consumption that minimises health loss due to alcohol use is
zero. These findings strongly suggest that alcohol control
policies should aim to reduce total population-level
consumption. To potentially reduce the effects of alcohol use
on future health loss, there is a need for countries to revisit
their alcohol control policies and assess how they can be
modified to further lower population-level consumption.
Figure 1: Age-standardised prevalence of current drinking for females (A)
and males (B) in 2016, in 195 locations
Current drinkers are defined as individuals who reported having consumed
alcohol within the past 12 months. ATG=Antigua and Barbuda. VCT=Saint
Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia.
LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
Articles
www.thelancet.com Vol 392 September 22, 2018
1017
A
Persian Gulf
The Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian Gulf
The Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
0–19·9
20·0–39·9
40·0–59·9
60·0–79·9
80·0–100·0
Current drinker prevalence (%)
Females
BMales
0–19·9
20·0–39·9
40·0–59·9
60·0–79·9
80·0–100·0
Current drinker prevalence (%)
Articles
1018
www.thelancet.com Vol 392 September 22, 2018
A
B
Persian Gulf
The Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian Gulf
The Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Females
Males
<1·00
1·01–2·00
2·01–3·00
Population average of standard drinks daily
3·01–4·00
4·01–5·00
>5·00
<1·00
1·01–2·00
2·01–3·00
Population average of standard drinks daily
3·01–4·00
4·01–5·00
>5·00
Articles
www.thelancet.com Vol 392 September 22, 2018
1019
prevalence of current drinking (having one or more
drinks in the past year); abstention from alcohol (having
no alcohol in the past year); the distribution of alcohol
consumption among current drinkers in standard drinks
daily; and the disease burden attributable to alcohol use,
in terms of deaths and disability-adjusted life-years
(DALYs). We produced these estimates for 195 locations
from 1990 to 2016, for both sexes and for 5-year age
groups between the ages of 15 years and 95 years and
older. We also did a new meta-analysis to assess the dose–
response risk of alcohol consumption for 23 outcomes.
Lastly, we estimated the level of alcohol consumption that
minimises an individual’s total attributable risk of any
health loss.
Methods
Study design
This study follows the comparative risk assessment
framework developed in previous iterations of GBD.20 In
the following sections, we summarise our methods and
briefly present innovations. A full explanation is available
in appendix 1. This study fully adheres to the Guidelines
for Accurate and Transparent Health Estimates Reporting
(GATHER) statement.21
We estimated alcohol use exposure as grams of pure
ethanol consumed daily by current drinkers (which we
present here in terms of standard drinks daily, defined as
10 g of pure ethyl alcohol). We estimated relative risks by
dose in grams of pure ethyl alcohol, for each included
risk–outcome pair. We ascertained which cause and
injury outcomes to include by reviewing prospective and
observational studies of alcohol use, and then assessing
the causal association using Bradford-Hill’s criteria for
causation.22 We included 23 outcomes, and the full list of
risk–outcome pairs, as well as the corresponding data
sources, are provided in appendix 1 (pp 52–140).
Data sources
We found sources that included indicators of current
drinking prevalence and alcohol consumed in grams per
day using the Global Health Data Exchange (GHDx) and
PubMed.23 For the meta-analysis, we searched PubMed,
the GHDx, and references of previously published meta-
analyses. For our exposure estimates, we extracted
121 029 data points from 694 sources across all exposure
indicators. For our relative risk estimates, we extracted
3992 relative risk estimates across 592 studies. These
relative risk estimates corresponded to a combined study
population of 28 million individuals and 649 000 registered
cases of respective outcomes. We list all the included data
sources in appendix 1 (pp 52–140).
To estimate standard drinks consumed daily by current
drinkers, we followed the general approach used by Rehm
and colleagues.18 We briefly explain this method here,
along with two methodological innovations to account
for bias in the sales model: an adjustment to account for
tourist consumption and an updated adjustment for
unrecorded consumption. A full explanation of this
approach is available in appendix 1 (pp 18–49).
To estimate exposure, we combined estimates of
population-level alcohol stock and individual-level alcohol
consumption to produce standard drinks consumed daily
among current drinkers and current drinker prevalence,
within a specific location, year, age group, and sex. We
started by estimating population-level alcohol stock in litres
per capita from sales data, individual-level estimates of the
prevalence of current drinkers and abstainers from survey
data, and individual-level estimates of the amount of
alcohol consumed in grams per day from survey data.
Then, for a given location and year, we rescaled age-specific
and sex-specific estimates of individual-level consumption
so that they aggregated to the estimates of population-level
consumption. When surveys reported amount consumed
in terms of beverage types, we converted these data into
grams of pure ethanol using density equations and
assumptions of the average alcohol content by drink type
(appendix 1, p 50). Finally, we rescaled estimates of current
drinking and abstention so that, within a given location,
year, age group, and sex, the two estimates summed to one.
After we derived our model of population-level alcohol
stock from sales data, we controlled for sources of bias
that could arise from tourism and unrecorded con-
sumption not recorded in formal sales. To account for
tourist consumption, we computed an additive measure
for alcohol consumed abroad by domestic citizens and
subtractive measures for alcohol consumed domestically
by tourists. We extracted data on the number of tourists
by country of origin and destination from the World
Tourism Organization and used these data to obtain
estimates of total tourists, percentage of tourists by
location, and average duration of stay using a spatio-
temporal Gaussian process regression.24 We combined
these estimates with measures of alcohol in litres per
capita by location, to calculate net amounts of total
population-level alcohol stock consumed by tourists or
domestic citizens travelling abroad.
To account for alcohol stock not captured within formal
alcohol sales data (ie, unrecorded consumption from
illicit production, home brewing, local beverages, or
alcohol sold as a non-alcohol product), we collated
estimates across published studies of the percentage of
total alcohol stock due to unrecorded consumption. We
sampled 1000 times from a uniform distribution with a
range between zero and the average of these collated
studies by location (sampling from the uncertainty
interval from each study, then averaging the draws) to
Figure 2: Average standard drinks (10 g of pure ethanol per serving)
consumed per day, age-standardised, for females (A) and males (B) in 2016,
in 195 locations
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands.
FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and
Tobago. TLS=Timor-Leste.
See Online for appendix 1
For more on the Global Health
Data Exchange see http://ghdx.
healthdata.org/
Articles
1020
www.thelancet.com Vol 392 September 22, 2018
generate a conservative estimate of the total stock likely
to be unrecorded. We used a conservative approach
because of the wide heterogeneity in both the methods
and estimates within included data sources. We provide
estimates of these percentages in appendix 1 (pp 46–49).
Systematic review and meta-analysis
We did a new systematic review for each associated
outcome to incorporate new findings on risk and to
improve upon existing approaches. This strategy allowed
us to systematically control for reference category con-
founding in constituent studies across associated out-
comes. We provide the search strategy, search diagrams,
dose–response curves for each included outcome, and
references for each outcome in appendix 1 (pp 57–146).
Drawing from our systematic review, we did a meta-
analysis of risk outcomes for alcohol use. For each
outcome, we estimated the dose–response relative risk
curve using mixed-eects logistic regression with non-
linear splines for doses between 0 and 12·5 standard
drinks daily. We selected 12·5 standard drinks daily as a
cuto point given the absence of available data beyond
this range. We present additional details of the model in
appendix 1 (pp 51–138). We tested the significance of
including a study-level confounding variable on the
composition of the reference category (eg, whether former
drinkers were included in the abstainer category or not).
When found to be significant, this variable was included
as a predictor within the model, which was the case for
ischaemic heart disease, ischaemic stroke, and diabetes.
Using our dose–response curves, we estimated the
consumption level that minimises harm, which is
defined in the comparative risk assessment approach as
the theoretical minimum risk exposure level (TMREL).
We chose a theoretical minimum on the basis of a
weighted average relative risk curve across all attributable
outcomes. We constructed weights for each risk outcome
based on the respective global, age-standardised DALY
rate per 100 000 in 2016 for both sexes. Our TMREL was
the minimum of this weighted all-attributable outcome
dose–response curve.
Attributable burden due to alcohol use
We calculated PAFs using our estimates of exposure,
relative risks, and TMREL, following the same approach
taken within the GBD studies.20 For alcohol-use disorders,
which are by definition fully attributable, we assumed a
PAF of 1.24 Following this calculation, we multiplied PAFs
by outcome-specific estimates of deaths and DALYs and
summed these across outcomes to calculate the total
attributable burden in specific locations. We aggregated
both exposure and burden results at the global level and
have presented them by quintile of the Socio-demographic
Index (SDI). SDI is a summary measure of overall
development, based on educational attainment, fertility,
and income per capita within a location. Locations
categorised by SDI quintile are found in appendix 1
(pp 8–12).25 We also constructed age-standardised values
of all estimates, using the same age weights as those used
in the GBD standard population.
We made one adjustment to road injury PAFs to estimate
how much burden occurred to others because of alcohol
use by another individual. We based this adjustment on
data from the US Fatality Analysis Reporting System
(FARS), which includes the average number of deaths in
automobile accidents involving alcohol and the percentage
of those deaths distributed by age and sex. We multiplied
age-specific and sex-specific alcohol-attributable and road-
injury-attributable DALYs by the average number of
fatalities, given the driver’s age and sex. We then re-
distributed these attributable DALYs according to the
FARS-derived probabilities that a population by age and
sex would be involved in a road injury, given the exposed
driver’s age and sex. Because of data availability, we
assumed that locations outside the USA would follow a
similar pattern to what we estimated with FARS. After
redistributing the attributable DALYs, we derived PAFs
again by dividing the redistributed attributable DALYs by
total DALYs within specific demographics.
Uncertainty analysis
For all steps, we calculated uncertainty for estimation
of exposure, attributable deaths, and DALYs by taking
1000 draws from the data’s uncertainty due to sampling
error and modelling uncertainty arising from hyper-
parameter selection and parameter estimation. We
then used these draws throughout the entire modelling
process. When reporting uncertainty intervals, we
present the 2·5th and 97·5th percentiles of the draws.
Role of the funding source
The funders of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
access to all the data in the study and had final
responsibility for the decision to submit for publication.
Results
Global, regional, and national trends in alcohol
consumption
In 2016, 32·5% (95% uncertainty interval [UI] 30·0–35·2)
of people globally were current drinkers. 25% (95% UI
23–27) of females were current drinkers, as were
39% (36–43) of males (appendix 2). These percentages
corresponded to 2·4 billion (95% UI 2·2–2·6) people
globally who were current drinkers, with 1·5 billion
(1·4–1·6) male current drinkers and 0·9 billion (0·8–1·0)
female current drinkers (appendix 2, pp 2–1994). Globally,
the mean amount of alcohol consumed was 0·73 (95% UI
0·68–0·78) standard drinks daily for females and
1·7 (1·5–1·9) standard drinks daily for males.
The prevalence of current drinking varied considerably
by location (figure 1). Prevalence was highest for high
SDI locations, where 72% (95% UI 69–75) of females and
For more on the US Fatality
Analysis Reporting System see
https://www.nhtsa.gov/research-
data/fatality-analysis-reporting-
system-fars
See Online for appendix 2
Articles
www.thelancet.com Vol 392 September 22, 2018
1021
–2000
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
Attributable DALY rate (per 100 000)
0
2000
Global High SDI High-to-middle SDI
–2000
Attributable DALY rate (per 100 000)
0
2000
Age group (years) Age group (years) Age group (years)
Middle SDI Low-to-middle SDI Low SDI
AFemales
Breast cancer
Colon and rectum cancer
Lip and oral cavity cancer
Pharynx and nasopharynx cancer
Ischaemic heart disease
Ischaemic stroke
Haemorrhagic stroke
Hypertensive heart disease
Atrial fibrillation and flutter
Cirrhosis and other chronic liver diseases
Pancreatitis
Epilepsy
Alcohol use disorders
Diabetes
Transport injuries
Unintentional injuries
Self harm
Interpersonal violence
Cause
Tuberculosis
Lower respiratory infections
Oesophageal cancer
Liver cancer
Larynx cancer
Figure 3 continues on next page
Articles
1022
www.thelancet.com Vol 392 September 22, 2018
2500
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
15–19
20–24
25–29
30–34
35–39
40–44
45–49
5054
55–59
60–64
65–69
70–74
75–79
80–84
85–89
90–94
≥95
Attributable DALY rate (per 100 000)
0
5000
7500
7500
Global High SDI High-to-middle SDI
Attributable DALY rate (per 100 000)
0
5000
Age group (years)
2500
Age group (years) Age group (years)
Middle SDI Low-to-middle SDI Low SDI
BMales
Breast cancer
Colon and rectum cancer
Lip and oral cavity cancer
Pharynx and nasopharynx cancer
Ischaemic heart disease
Ischaemic stroke
Haemorrhagic stroke
Hypertensive heart disease
Atrial fibrillation and flutter
Cirrhosis and other chronic liver diseases
Pancreatitis
Epilepsy
Alcohol use disorders
Diabetes
Transport injuries
Unintentional injuries
Self harm
Interpersonal violence
Cause
Tuberculosis
Lower respiratory infections
Oesophageal cancer
Liver cancer
Larynx cancer
Articles
www.thelancet.com Vol 392 September 22, 2018
1023
83% (80–85) of males were current drinkers (locations
com prising each SDI quintile are provided in appendix 2,
pp 8–12). Drinking prevalence was lowest in low-to-
middle SDI locations, where 8·9% (95% UI 6·6–9·7) of
females and 20% (17–22) of males were current drinkers.
Across SDI quintiles, females consumed less alcohol
than males, with the size of this disparity decreasing with
higher levels of SDI. For example, we found large
dierences between females and males in Nepal, with
only 1·5% (95% UI 1·2–1·9) of females being current
drinkers in 2016, compared with 21% (17–25) of males.
Conversely, many high SDI locations had similar
prevalence between sexes. For example, we found
minimal dierences in Sweden, where 86% (95% UI
84–88) of females and 87% (85–89) of males were current
drinkers.
The population average of standard drinks consumed
daily among current drinkers in 2016 also diered widely
by location and sex (figure 2). High SDI locations had
the highest average of standard drinks consumed daily,
with 1·9 (95% UI 1·3–2·7) standard drinks consumed
daily among females and 2·9 (2·0–4·1) among males.
Low SDI locations had the smallest average for males,
with 1·4 (0·6–2·4) standard drinks consumed daily,
while low-to-middle SDI locations had the lowest average
for females, with 0·3 (0·1–0·6) standard drinks
consumed daily.
Global patterns in alcohol-attributable deaths and
disease burden
In 2016, 2·8 million deaths (95% UI 2·4–3·3) were
attributed to alcohol use. This corresponds to 2·2%
(95% UI 1·5–3·0) of total age-standardised deaths among
females and 6·8% (5·8–8·0) among males. In terms of
overall disease burden, alcohol use led to 1·6% (95% UI
1·4–2·0) of total DALYs globally in 2016 among females
and 6·0% (5·4–6·7) among males. Globally, alcohol use
was ranked as the seventh leading risk factor for
premature death and disability in 2016, compared with
other risk factors in the GBD studies. Among the
population aged 15–49 years, alcohol use was the leading
global risk factor for risk-attributable disease burden,
causing 8·9% (95% UI 7·8–9·9) of attributable DALYs for
men and 2·3% (2·0–2·6) for women. Among the
population aged 15–49 years, 3·8% (95% UI 3·2–4·3) of
female deaths and 12·2% (10·8–13·6) of male deaths
were attributable to alcohol use.
Both total burden attributable to alcohol use and the
proportion of causes associated with alcohol use varied
by sex, age, and SDI quintile (figure 3; appendix 2,
pp 1997–2186). In absolute terms, the alcohol-attributable
burden by age was smaller for females than for males
(figure 3). For females, the alcohol-attributable burden
increased with age, while for males the burden increased
until between 55–65 years of age, after which attributable
burden decreased. Females, particularly in high SDI
locations, experienced some protective eects for
ischaemic heart disease and diabetes beyond 60 years of
age. For males, only high SDI and low SDI locations had
noticeable protective eects for ischaemic heart disease,
but the eect was small compared with the total
attributable burden in those locations.
For both males and females, health outcomes com-
prising the attributable burden changed across the life-
span (figure 3). The three leading causes of attributable
deaths in this age group were tuberculosis (1·4% [95% UI
1·0–1·7] of total deaths), road injuries (1·2% [0·7–1·9]),
and self-harm (1·1% [0·6–1·5]). For females aged
15–49 years, alcohol use disorders con stituted the largest
proportion of the attributable burden across SDI
quintiles; the primary exception was tuber culosis, which
accounted for the largest proportion of attributable
burden in low SDI settings. In this age range, transport
injuries and alcohol use disorders were the predominant
causes of attributable burden for males in high-to-middle
SDI quintiles; for low-to-middle SDI and low SDI
quintiles, tuberculosis was the primary cause of the
attributable burden for both sexes.
Beyond 50 years of age, the causes of total attributable
burden became more complex by SDI quintile. For
populations aged 50 years and older, cancers accounted
for a large proportion of total alcohol-attributable deaths
in 2016, constituting 27·1% (95% UI 21·2–33·3) of
total alcohol-attributable female deaths and 18·9%
(15·3–22·6) of alcohol-attributable male deaths. In high
SDI countries, cancers were the predominant source of
attributable burden among both sexes. In low SDI
countries, tuberculosis was the primary cause of burden
for both sexes, followed by cirrhosis and other chronic
liver diseases. The profile of attributable burden in high-
to-middle SDI and middle SDI countries for females
and males was largely composed of ischaemic stroke
and haemorrhagic stroke, followed by liver cancer for
females. In all SDI quintiles, haemorrhagic stroke and
hypertensive heart disease were the largest sources of
burden for females aged 80 years and older. For men in
this age group, the composition of the burden was
similar to that of males aged 50 years or older.
Health risks associated with alcohol consumption
Figure 4 shows the relative risk curves for selected health
outcomes, separately for females and males. Estimated
relative risk curves for each health outcome are presented
in appendix 2 (pp 52–140). With this analysis, we only
found statistically significant evidence for the J-shaped
curve for ischaemic heart disease; non-significant
J-shaped curves were observed for diabetes and isch-
aemic stroke. For ischaemic heart disease, we found a
Figure 3: Attributable DALY rate disaggregated by outcome, shown globally
and for each region, by age and sex, in 2016
(A) Females. (B) Males. DALY=disability-adjusted life-year. SDI=Socio-demographic
Index.
Articles
1024
www.thelancet.com Vol 392 September 22, 2018
01 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
Relative risk
Standard drinks daily
0·3
0·6
0·9
1·2
1·5
1·8
2·4
2·1
A Females
B Males *
Breast cancer
01 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
Standard drinks daily
0·4
0·8
1·2
1·6
2·0
2·4
3·2
2·8
Ischaemic heart disease
0
Relative risk
0·4
0·8
1·2
1·6
2·0
2·4
3·2
3·6
2·8
Diabetes
0
0·9
1·8
2·7
3·6
4·5
5·4
6·3
8·1
9·0
7·2
Tuberculosis
0
Relative risk
2
4
6
8
10
14
12
Lip and oral cavity cancer
0
0·3
0·6
0·9
1·2
1·5
2·1
1·8
Ischaemic heart disease
0
Relative risk
0·3
0·6
0·9
1·2
1·5
1·8
2·1
Diabetes
0
0·9
1·8
2·7
3·6
4·5
5·4
9·0
6·3
8·1
7·2
Tuberculosis
Articles
www.thelancet.com Vol 392 September 22, 2018
1025
minimum relative risk of 0·86 (0·80–0·96) for men and
0·82 (0·72–0·95) for women, occurring at 0·83 standard
drinks daily for men and 0·92 standard drinks daily for
women. We found no significant dierence in relative
risk curves for ischaemic heart disease or diabetes
when estimating the curves by age. For all other out-
comes, including all cancers, we found that relative risk
monotonically increased with alcohol consumption
(appendix 2, pp 57–146).
In estimating the weighted relative risk curve, we
found that consuming zero (95% UI 0·0–0·8) standard
drinks daily minimised the overall risk of all health
loss (figure 5). The risk rose monotonically with
increasing amounts of daily drinking. This weighted
relative risk curve took into account the protective eects
of alcohol use associated with ischaemic heart disease
and diabetes in females. However, these protective
eects were oset by the risks associated with cancers,
which in creased monotonically with consumption. In a
sensitivity analysis, where we explored how the weighted
relative risk curve changed on the basis of the choice of
weights for various health outcomes, the curve changed
signifi cantly only in settings where diabetes and
ischaemic heart disease comprised more than 60% of
total deaths in a population.
Discussion
In 2016, alcohol use led to 2·8 million deaths and was the
leading risk factor for premature death and disability
among people aged 15–49 years, with nearly 9% of all
attributable DALYs for men and more than 2% for
women. Our findings indicate that alcohol use was
associated with far more health loss for males than for
females, with the attributable burden for men around
three times higher than that for women in 2016. By
evaluating all associated relative risks for alcohol use, we
found that consuming zero standard drinks daily
minimises the overall risk to health.
Previous research has analysed all-cause risk due to
alcohol use by either investigating all-cause risk in
particular cohorts and survey series, or through meta-
analyses of those studies.26,27 Past findings subsequently
suggested a persistent protective eect for some low or
moderate levels of alcohol consumption on all-cause
mortality. However, these studies were limited by
small sample sizes, inadequate control for confounders,
and non-optimal choices of a reference category for
calculating relative risks. More recent research, which
has used methodologies such as mendelian randomis-
ation, pooling cohort studies, and multivariable adjusted
meta-analyses, increasingly shows either a non-signifi-
cant or no protective eect of drinking on all-cause
mortality or cardiovascular outcomes.7,14,28 Our results on
the weighted attributable risk are consistent with this
body of work. Taken together, these findings emphasise
that alcohol use, regardless of amount, leads to health
loss across populations. Although we found some
protective eects for ischaemic heart disease and
diabetes among women, these eects were oset when
overall health risks were considered—especially because
of the strong association between alcohol consump-
tion and the risk of cancer, injuries, and communic-
able disease. These findings stress the importance of
assessing how alcohol use aects population health
across the lifespan.
Evaluating attributable burden across SDI quintiles
revealed the magnitude by which outcomes of alcohol
use dier and how total attributable burden relates to
increasing SDI. Our results indicate that alcohol use and
its harmful eects on health could become an increasing
challenge amid gains in SDI. Given that most low and
low-to-middle SDI settings currently have lower average
alcohol consumption than high-to-middle SDI settings,
it is crucial for decision makers and government agencies
to enact or maintain strong alcohol control policies today
to prevent the potential for rising alcohol use in the
future. Eective policies now could yield substantial
population health benefits for years to come.
Figure 4: Relative risk curves for selected conditions by number of standard
drinks consumed daily
(A) Relative risk curves for breast cancer, ischaemic heart disease, diabetes,
and tuberculosis for females. (B) Relative risk curves for lip and oral cavity cancer,
ischaemic heart disease, diabetes, and tuberculosis for males. Points are relative
risk estimates from studies. The vertical and horizontal bars capture the
uncertainty in each study, related to the sample size and number of drinks
consumed by individuals in the study. The black line represents the estimated
relative risk for each condition at each level of consumption. The shaded green
areas represent the 95% uncertainty interval associated with the estimated
relative risk. The dotted line is a reference line for a relative risk of 1. The relative
risk curves for all other health outcomes associated with alcohol use are
presented in appendix 2 (pp 57–146).
01 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1·0
Relative risk
Standard drinks daily
1·5
2·0
2·5
3·0
3·5
4·0
4·5
Figure 5: Weighted relative risk of alcohol for all attributable causes, by
standard drinks consumed per day
Age-standardised weights determined by the DALY rate in 2016, for both sexes.
The dotted line is a reference line for a relative risk of 1. DALY=disability-adjusted
life-year.
Articles
1026
www.thelancet.com Vol 392 September 22, 2018
Our results point to a need to revisit alcohol control
policies and health programmes, and to consider
recommendations for abstention. In terms of reducing
population-level alcohol use, WHO provides a set of best
buys—policies that provide an individual year of healthy
life at less than the cost of the average individual
income.29 Governments should consider how these
recommendations can be implemented within their local
contexts and broader policy platforms, including excise
taxes on alcohol, controlling the physical availability of
alcohol and the hours of sale, and controlling alcohol
advertising. Any of these policy actions would contribute
to reductions in population-level consumption—an
important step toward decreasing the health loss
associated with alcohol use.
Failing to address harms from alcohol use, particularly
at high levels of consumption, can have dire eects on
population health. The mortality crisis in Russia is a
striking example, where alcohol use was the primary
culprit of increases in mortality starting in the 1980s and
led to 75% of deaths among men aged 15–55 years.30
Current global trends—namely, population ageing—
portend a growing toll of the alcohol-attributable burden
in the absence of policies, particularly since many cancers
disproportionately aect older individuals. Consequently,
low-to-middle SDI countries could benefit from policy
action today to keep alcohol consump tion low and
prevent greater health loss in the future. High and
high-to-middle SDI locations need to consider stronger
alcohol reduction policies, such as those recommend-
ed by WHO, in an eort to reduce population-level
consumption.
Our results should be interpreted within the context of
the study’s limitations. First, our consumption estimates
might not fully capture illicit production or unrecorded
consumption given our use of sales data in estimation.
We have sought to adjust for consumption beyond sales
data, but given the heterogeneity of these estimates it is
likely that additional methodological refinements are
necessary to improve the quantification of unrecorded
consumption. Second, drinking patterns within a year
are assumed to be consistent; however, past work shows
that drinking patterns, rather than average levels of
consumption such as standard daily drinks, might be
related to dierent levels of risk and harm. Unfortunately,
the data requirements for assessment of such drinking
patterns by age, sex, and location far exceed what is
currently available. For instance, few prospective studies
quantify the eects of drinking patterns and average
levels of consumption in tandem, a requirement for
correctly assessing the risk of alcohol-attributable
outcomes. Third, the data used to estimate motor vehicle
harm caused to others from alcohol use were only
available for the USA (ie, FARS data). Although it is
unlikely that the patterns observed in FARS are drastically
dierent from those of other locations (appendix 1,
pp 141–144), this assumption needs to be tested with
more location-specific estimates. Fourth, we were unable
to find robust data about the harm caused to others
from alcohol-attributable interpersonal violence, a major
potential source of health loss. More retrospective studies
are needed to assess the harm to others caused through
an individual’s alcohol use.30 Fifth, consumption for
populations younger than 15 years was not assessed
because of data sparseness on alcohol use for these age
groups. In the absence of such data, potential approaches
to address this limitation, such as assuming consumption
patterns of older age groups or trying to extrapolate past
levels of alcohol consumption, are likely to introduce
additional bias or error. More research on youth drinking
and the associated risk is required to estimate alcohol-
attributable burden for this age group. Last, we sought to
quantify the risk of alcohol use only for outcomes with
evidence meeting the criteria for the comparative risk
assessment approach of GBD studies. However, there are
additional outcomes, such as dementia and psoriasis,
for which accumulating evidence suggests that alcohol
use might be a risk factor.31–33 In combination, these
limitations suggest that our results are likely to under-
estimate both the health risks and overall attributable
burden of alcohol use.
Conclusion
Alcohol use is a leading risk factor for disease burden
worldwide, accounting for nearly 10% of global deaths
among populations aged 15–49 years, and poses dire
ramifications for future population health in the absence
of policy action today. The widely held view of the health
benefits of alcohol needs revising, particularly as
improved methods and analyses continue to show how
much alcohol use contributes to global death and
disability. Our results show that the safest level of
drinking is none. This level is in conflict with most
health guidelines, which espouse health benefits
associated with consuming up to two drinks per day.
Alcohol use contributes to health loss from many causes
and exacts its toll across the lifespan, particularly among
men. Policies that focus on reducing population-level
consumption will be most eective in reducing the
health loss from alcohol use.
GBD 2016 Alcohol Collaborators
Max G Griswold, Nancy Fullman, Caitlin Hawley, Nicholas Arian,
Stephanie R M Zimsen, Hayley D Tymeson, Vidhya Venkateswaran,
Austin Douglas Tapp, Mohammad H Forouzanfar, Joseph S Salama,
Kalkidan Hassen Abate, Degu Abate, Solomon M Abay,
Cristiana Abbafati, Rizwan Suliankatchi Abdulkader, Zegeye Abebe,
Victor Aboyans, Mohammed Mehdi Abrar, Pawan Acharya,
Olatunji O Adetokunboh, Tara Ballav Adhikari, Jose C Adsuar,
Mohsen Afarideh, Emilie Elisabet Agardh, Gina Agarwal,
Sargis Aghasi Aghayan, Sutapa Agrawal, Muktar Beshir Ahmed,
Mohammed Akibu, Tomi Akinyemiju, Nadia Akseer, Deena H Al Asfoor,
Ziyad Al-Aly, Fares Alahdab, Khurshid Alam, Ammar Albujeer,
Kefyalew Addis Alene, Raghib Ali, Syed Danish Ali, Mehran Alijanzadeh,
Syed Mohamed Aljunid, Ala’a Alkerwi, Peter Allebeck,
Nelson Alvis-Guzman, Azmeraw T Amare, Leopold N Aminde,
Walid Ammar, Yaw Ampem Amoako, Gianna Gayle Herrera Amul,
Catalina Liliana Andrei, Colin Angus, Mustafa Geleto Ansha,
Articles
www.thelancet.com Vol 392 September 22, 2018
1027
Carl Abelardo T Antonio, Olatunde Aremu, Johan Ärnlöv, Al Artaman,
Krishna K Aryal, Reza Assadi, Marcel Ausloos, Leticia Avila-Burgos,
Euripide F G A Avokpaho, Ashish Awasthi, Henok Tadesse Ayele,
Rakesh Ayer, Tambe B Ayuk, Peter S Azzopardi, Hamid Badali,
Alaa Badawi, Maciej Banach, Suzanne Lyn Barker-Collo, Lope H Barrero,
Huda Basaleem, Estifanos Baye, Shahrzad Bazargan-Hejazi,
Neeraj Bedi, Yannick Béjot, Abate Bekele Belachew, Saba Abraham Belay,
Derrick A Bennett, Isabela M Bensenor, Eduardo Bernabe,
Robert S Bernstein, Addisu Shunu Beyene, Tina Beyranvand,
Soumyadeeep Bhaumik, Zulfiqar A Bhutta, Belete Biadgo, Ali Bijani,
Nigus Bililign, Sait Mentes Birlik, Charles Birungi,
Hailemichael Bizuneh, Peter Bjerregaard, Tone Bjørge,
Guilherme Borges, Cristina Bosetti, Soufiane Boufous,
Nicola Luigi Bragazzi, Hermann Brenner, Zahid A Butt,
Lucero Cahuana-Hurtado, Bianca Calabria, Ismael R Campos-Nonato,
Julio Cesar Campuzano Rincon, Giulia Carreras, Juan J Carrero,
Félix Carvalho, Carlos A Castañeda-Orjuela, Jacqueline Castillo Rivas,
Ferrán Catalá-López, Jung-Chen Chang, Fiona J Charlson,
Aparajita Chattopadhyay, Pankaj Chaturvedi, Rajiv Chowdhury,
Devasahayam J Christopher, Sheng-Chia Chung, Liliana G Ciobanu,
Rafael M Claro, Sara Conti, Ewerton Cousin, Michael H Criqui,
Berihun Assefa Dachew, Paul I Dargan, Ahmad Daryani,
José Das Neves, Kairat Davletov, Filipa De Castro, Barbora De Courten,
Jan-Walter De Neve, Louisa Degenhardt, Gebre Teklemariam Demoz,
Don C Des Jarlais, Subhojit Dey, Rupinder Singh Dhaliwal,
Samath Dhamminda Dharmaratne, Meghnath Dhimal,
David Teye Doku, Kerrie E Doyle, Manisha Dubey, Eleonora Dubljanin,
Bruce B Duncan, Hedyeh Ebrahimi, Dumessa Edessa,
Maysaa El Sayed Zaki, Sergei Petrovich Ermakov, Holly E Erskine,
Alireza Esteghamati, Mahbobeh Faramarzi, Andrea Farioli, Andre Faro,
Maryam S Farvid, Farshad Farzadfar, Valery L Feigin,
Mariana Santos Felisbino-Mendes, Eduarda Fernandes, Alize J Ferrari,
Cleusa P Ferri, Daniel Obadare Fijabi, Irina Filip, Jonas David Finger,
Florian Fischer, Abraham D Flaxman, Richard Charles Franklin,
Neal D Futran, Silvano Gallus, Morsaleh Ganji,
Fortune Gbetoho Gankpe, Gebremedhin Berhe Gebregergs,
Tsegaye Tewelde Gebrehiwot, Johanna M Geleijnse, Reza Ghadimi,
Lilian A Ghandour, Mamata Ghimire, Paramjit Singh Gill,
Ibrahim Abdelmageed Ginawi, Ababi Zergaw Z Giref, Philimon N Gona,
Sameer Vali Gopalani, Carolyn C Gotay, Alessandra C Goulart,
Felix Greaves, Giuseppe Grosso, Yuming Guo, Rahul Gupta,
Rajeev Gupta, Vipin Gupta, Reyna Alma Gutiérrez, Murthy Gvs,
Nima Hafezi-Nejad, Tekleberhan Beyene Hagos,
Gessessew Bugssa Hailu, Randah R Hamadeh, Samer Hamidi,
Graeme J Hankey, Hilda L Harb, Sivadasanpillai Harikrishnan,
Josep Maria Haro, Hamid Yimam Hassen, Rasmus Havmoeller,
Simon I Hay, Behzad Heibati, Andualem Henok, Ileana Heredia-Pi,
Norberto Francisco Hernández-Llanes, Claudiu Herteliu,
Desalegn Ts Tsegaw Hibstu, Praveen Hoogar, Nobuyuki Horita,
H Dean Hosgood, Mostafa Hosseini, Mihaela Hostiuc, Guoqing Hu,
Hsiang Huang, Abdullatif Husseini, Bulat Idrisov, Bogdan Vasile Ileanu,
Olayinka Stephen Ilesanmi, Seyed Sina Naghibi Irvani,
Sheikh Mohammed Shariful Islam, Maria D Jackson,
Mihajlo Jakovljevic, Achala Upendra Jayatilleke, Ravi Prakash Jha,
Jost B Jonas, Jacek Jerzy Jozwiak, Zubair Kabir, Rajendra Kadel,
Amaha Kahsay, Umesh Kapil, Amir Kasaeian, Tesfaye D Dessale Kassa,
Srinivasa Vittal Katikireddi, Norito Kawakami, Seifu Kebede,
Adane Teshome Kefale, Peter Njenga Keiyoro, Andre Pascal Kengne,
Yousef Khader, Morteza Abdullatif Khafaie, Ibrahim A Khalil,
Md Nuruzzaman Khan, Young-Ho Khang, Mona M Khater,
Jagdish Khubchandani, Cho-Il Kim, Daniel Kim, Yun Jin Kim,
Ruth W Kimokoti, Adnan Kisa, Mika Kivimäki, Sonali Kochhar,
Soewarta Kosen, Parvaiz A Koul, Ai Koyanagi, Kewal Krishan,
Barthelemy Kuate Defo, Burcu Kucuk Bicer, Veena S Kulkarni,
Pushpendra Kumar, Alessandra Lafranconi, Arjun Lakshmana Balaji,
Ratilal Lalloo, Tea Lallukka, Hilton Lam, Faris Hasan Lami, Qing Lan,
Justin J Lang, Sonia Lansky, Anders O Larsson, Arman Latifi,
Janet L Leasher, Paul H Lee, James Leigh, Mall Leinsalu, Janni Leung,
Miriam Levi, Yichong Li, Lee-Ling Lim, Shai Linn, Shiwei Liu,
Andrea Lobato-Cordero, Paulo A Lotufo, Erlyn Rachelle King Macarayan,
Isis Eloah Machado, Fabiana Madotto, Hassan Magdy Abd El Razek,
Muhammed Magdy Abd El Razek, Marek Majdan, Reza Majdzadeh,
Azeem Majeed, Reza Malekzadeh, Deborah Carvalho Malta,
Chabila Christopher Mapoma, Jose Martinez-Raga, Pallab K Maulik,
Mohsen Mazidi, Martin Mckee, Varshil Mehta, Toni Meier,
Tesfa Mekonen, Kidanu Gebremariam Meles, Addisu Melese,
Peter T N Memiah, Walter Mendoza, Desalegn Tadese Mengistu,
George A Mensah, Tuomo J Meretoja, Haftay Berhane Mezgebe,
Tomasz Miazgowski, Ted R Miller, Gk Mini, Andreea Mirica,
Erkin M Mirrakhimov, Babak Moazen,
Karzan Abdulmuhsin Mohammad, Noushin Mohammadifard,
Shafiu Mohammed, Lorenzo Monasta, Paula Moraga, Lidia Morawska,
Moti Tolera Jalu, Seyyed Meysam Mousavi, Satinath Mukhopadhyay,
Kamarul Imran Musa, Aliya Naheed, Gurudatta Naik, Farid Najafi,
Vinay Nangia, Jobert Richie Nansseu,
Mudavath Siva durga prasad Nayak, Chakib Nejjari, Subas Neupane,
Sudan Prasad Neupane, Josephine W Ngunjiri, Cuong Tat Nguyen,
Long Hoang Nguyen, Trang Huyen Nguyen,
Dina Nur Anggraini Ningrum, Yirga Legesse Nirayo,
Jean Jacques Noubiap, Richard Ofori-Asenso, Felix Akpojene Ogbo,
In-Hwan Oh, Olanrewaju Oladimeji, Andrew T Olagunju,
Pedro R Olivares, Bolajoko Olubukunola Olusanya,
Jacob Olusegun Olusanya, Anu Mary Oommen, Eyal Oren,
Heather M Orpana, Doris D V Ortega-Altamirano, Justin R Ortiz,
Erika Ota, Mayowa Ojo Owolabi, Abayomi Samuel Oyekale, Mahesh P A,
Adrian Pana, Eun-Kee Park, Charles D H Parry, Hadi Parsian, Ajay Patle,
George C Patton, Deepak Paudel, Max Petzold, Michael R Phillips,
Julian David Pillay, Maarten J Postma, Farshad Pourmalek,
Dorairaj Prabhakaran, Mostafa Qorbani, Amir Radfar, Anwar Rafay,
Alireza Rafiei, Fakher Rahim, Afarin Rahimi-Movaghar,
Mahfuzar Rahman, Muhammad Aziz Rahman, Rajesh Kumar Rai,
Sasa Rajsic, Sree Bhushan Raju, Usha Ram, Saleem M Rana,
Chhabi Lal Ranabhat, David Laith Rawaf, Salman Rawaf,
Robert C Reiner, Cesar Reis, Andre M N Renzaho,
Mohammad Sadegh Rezai, Leonardo Roever, Luca Ronfani,
Robin Room, Gholamreza Roshandel, Ali Rostami, Gregory A Roth,
Ambuj Roy, Yogesh Damodar Sabde, Basema Saddik, Saeid Safiri,
Amirhossein Sahebkar, Joseph S Salama, Zikria Saleem,
Joshua A Salomon, Sundeep Santosh Salvi, Juan Sanabria,
Maria Dolores Sanchez-Niño, Damian Francesco Santomauro,
Itamar S Santos, Milena M M Santric Milicevic, Abdur Razzaque Sarker,
Rodrigo Sarmiento-Suárez, Nizal Sarrafzadegan, Benn Sartorius,
Maheswar Satpathy, Monika Sawhney, Sonia Saxena, Mete Saylan,
Michael P Schaub, Maria Inês Schmidt, Ione J C Schneider,
Ben Schöttker, Aletta Elisabeth Schutte, Falk Schwendicke,
Sadaf G Sepanlou, Masood A Ali Shaikh, Mehdi Sharif, Jun She,
Aziz Sheikh, Jiabin Shen, Mekonnen Sisay Shiferaw, Mika Shigematsu,
Rahman Shiri, Kawkab Shishani, Ivy Shiue, Sharvari Rahul Shukla,
Inga Dora Sigfusdottir, Diego Augusto Santos Silva,
Natacha Torres Da Silva, Dayane Gabriele Alves Silveira,
Dhirendra Narain Narain Sinha, Freddy Sitas,
Adauto Martins Soares Filho, Moslem Soofi, Reed J D Sorensen,
Joan B Soriano, Chandrashekhar T Sreeramareddy, Nadine Steckling,
Dan J Stein, Mu’awiyyah Babale Sufiyan, Patrick J Sur, Bryan L Sykes,
Rafael Tabarés-Seisdedos, Takahiro Tabuchi, Mohammad Tavakkoli,
Arash Tehrani-Banihashemi, Merhawi Gebremedhin Tekle, Subash Thapa,
Nihal Thomas, Roman Topor-Madry, Fotis Topouzis, Bach Xuan Tran,
Christopher E Troeger, Thomas Clement Truelsen, Nikolaos Tsilimparis,
Stefanos Tyrovolas, Kingsley Nnanna Ukwaja, Irfan Ullah,
Olalekan A Uthman, Pascual R Valdez, Job F M Van Boven,
Tommi Juhani Vasankari, Narayanaswamy Venketasubramanian,
Francesco S Violante, Sergey Konstantinovitch Vladimirov, Vasily Vlassov,
Stein Emil Vollset, Theo Vos, Fasil Wagnew Shiferaw Wagnew,
Yasir Waheed, Yuan-Pang Wang, Elisabete Weiderpass,
Fitsum Weldegebreal, Kidu Gidey Weldegwergs, Andrea Werdecker,
Ronny Westerman, Harvey A Whiteford, Justyna Widecka, Tissa Wijeratne,
Grant M A Wyper, Gelin Xu, Tomohide Yamada, Yuichiro Yano,
Pengpeng Ye, Ebrahim M Yimer, Paul Yip, Biruck Desalegn Yirsaw,
Engida Yisma, Naohiro Yonemoto, Seok-Jun Yoon, Marcel Yotebieng,
Mustafa Z Younis, Geevar Zachariah, Zoubida Zaidi, Mohammad Zamani,
Xueying Zhang, Sanjay Zodpey, Ali H Mokdad, Mohsen Naghavi,
Christopher J L Murray, Emmanuela Gakidou.
Articles
1028
www.thelancet.com Vol 392 September 22, 2018
Affiliations
Institute for Health Metrics and Evaluation (M G Griswold MA,
N Fullman MPH, C Hawley MSPH, N Arian BS, S R M Zimsen MA,
H D Tymeson BA, A D Tapp BS, J S Salama MS,
Prof L Degenhardt PhD, S D Dharmaratne MD, Prof V L Feigin PhD,
Prof A D Flaxman PhD, Prof S I Hay DSc, Prof M Jakovljevic PhD,
I A Khalil MD, R C Reiner PhD, G A Roth MD, P J Sur BA,
C E Troeger MPH, Prof S Vollset DrPH, Prof T Vos PhD,
Prof H A Whiteford PhD, Prof A H Mokdad PhD, Prof M Naghavi PhD,
Prof C J L Murray DPhil, Prof E Gakidou PhD), Department of Global
Health (F J Charlson PhD, S Kochhar MD, Prof J R Ortiz MD,
R J D Sorensen MPH), School of Medicine Department of
Otolaryngology-Head and Neck Surgery (N D Futran MD), University of
Washington, Seattle, WA, USA (Prof E Oren PhD); Department of
Epidemiology (V Venkateswaran BDS), Department of Nutrition
(M S Farvid PhD), Ariadne Labs (E K Macarayan PhD), BWH Division of
General Internal Medicine and Primary Care (Prof A Sheikh MSc),
Harvard University, Boston, MA, USA; Seattle Genetics, Seattle, WA,
USA (M H Forouzanfar PhD); Department of Population and Family
Health (Prof K H Abate PhD), Department of Epidemiology
(M B Ahmed MPH, Prof T T Gebrehiwot MPH), Jimma University,
Jimma, Ethiopia; School of Public Health (A S Beyene MPH,
M G Tekle MPH), School of Pharmacy (D Edessa MSc,
Prof M S Shiferaw MSc), Department of Medical Laboratory Science
(Prof F Weldegebreal MSc), Haramaya University, Harar, Ethiopia
(D Abate MSc, M T Jalu MPH); Department of Pharmacology and
Clinical Pharmacy (S M Abay PhD), Department of Reproductive Health
and Health Service Management (A Z Z Giref PhD), School of Alaide
Health Sciences (Prof E Yisma MPH), Addis Ababa University, Addis
Ababa, Ethiopia (M M Abrar MS, G T Demoz MSc); Department of Law
Philosophy and Economic Studies, La Sapienza University, Rome, Italy
(Prof C Abbafati PhD); Department of Public Health
(R S Abdulkader MD), Oce of the Undersecretary of Health Aairs
(D H Al Asfoor MSc), Ministry of Health, Riyadh, Saudi Arabia; Human
Nutrition (Z Abebe MSc), Institute of Public Health
(Prof K A Alene MPH, Prof B A Dachew MPH), Department of Clinical
Chemistry (B Biadgo BSc), University of Gondar, Gondar, Ethiopia;
Department of Cardiology, Dupuytren University Hospital, Limoges,
France (Prof V Aboyans MD); Institute of Epidemiology, University of
Limoges, Limoges, France (Prof V Aboyans MD); Nepal Development
Society, Nepal (P Acharya MPH); Department of Global Health
(O O Adetokunboh MSc), Department of Psychiatry
(Prof C D H Parry PhD), Stellenbosch University, Cape Town, South
Africa; Cochrane South Africa (O O Adetokunboh MSc), Unit for
Hypertension and Cardiovascular Disease (Prof A E Schutte PhD),
South African Medical Research Council, Cape Town, South Africa
(Prof D J Stein MD); Nepal Health Research Environment, Center for
Social Science and Public Health Research Nepal, Nepal
(T B Adhikari MPH); Unit for Health Promotion Research
(T B Adhikari MPH), National Institute of Public Health
(Prof P Bjerregaard DrPH), Department of Public Health (S Thapa PhD),
University of Southern Denmark, Odense, Denmark; Faculty of Sport
Science, University of Extremadura, Spain (J C Adsuar PhD);
Endocrinology and Metabolism Research Center (M Afarideh MD,
H Ebrahimi MD, Prof A Esteghamati MD, M Ganji MD), Digestive
Disease Research Institute (H Ebrahimi MD), Non-Communicable
Diseases Research Center (F Farzadfar MD, S N Irvani MD), School of
Medicine (N Hafezi-Nejad MD), Hematologic Malignancies Research
Center (A Kasaeian PhD), Hematology-Oncology and Stem Cell
Transplantation Research Center (A Kasaeian PhD), Knowledge
Utilization Research Center (KURC) (Prof R Majdzadeh PhD), Digestive
Diseases Research Institute (Prof R Malekzadeh MD, G Roshandel PhD,
S G Sepanlou MD), Department of Health Management and Economics,
School of Public Health (S Mousavi PhD), Iranian National Center for
Addiction Studies (INCAS) (Prof A Rahimi-Movaghar MD),
Community-Based Participatory-Research Center (CBPR)
(Prof R Majdzadeh PhD), Tehran University of Medical Sciences,
Tehran, Iran (Prof M Hosseini PhD, Prof F Rahim PhD); Department of
Public Health Sciences (Prof E E Agardh PhD, Prof P Allebeck MD),
Department of Neurobiology (Prof J Ärnlöv PhD), Department of
Medical Epidemiology and Biostatistics (Prof J J Carrero PhD,
Prof E Weiderpass PhD), Karolinska Institute, Stockholm, Sweden;
Department of Family Medicine, McMaster University, Hamilton, ON,
Canada (G Agarwal MD); Chair of Zoology, Yerevan State University,
Yerevan, Armenia (S A Aghayan PhD); Research Group of Molecular
Parasitology, Scientific Center of Zoology and Hydroecology, Yerevan,
Armenia (S A Aghayan PhD); Indian Institute of Public Health
(Prof S Zodpey PhD), Public Health Foundation of India (PHFI),
Gurugram, India (S Agrawal PhD, A Awasthi PhD,
Prof D Prabhakaran DM); Vital Strategies, Gurugram, India
(S Agrawal PhD); Department of Midwifery (M Akibu MSc), Department
of Public Health, Lexington, KY, USA (M G Ansha MPH); Debre Berhan
University, Debre Berhan, Ethiopia; Department of Epidemiology,
University of Kentucky, USA (T Akinyemiju PhD); Nutritional Sciences,
Faculty of Medicine (A Badawi PhD), Centre for Global Child Health,
The Hospital for Sick Children, University of Toronto, Toronto, ON,
Canada (N Akseer PhD, Prof Z A Bhutta PhD); Nueld Department of
Population Health, University of Oxford, Oxford, UK
(D H Al Asfoor MSc, R Ali MPH, D A Bennett PhD); Department of
Internal Medicine, Washington University in St. Louis, Saint Louis, MO,
USA (Z Al-Aly MD); VA Saint Louis Health Care System, Clinical
Epidemiology Center, Department of Veterans Aairs, Saint Louis, MO,
USA (Z Al-Aly MD); Evidence Based Practice Center, Mayo Clinic
Foundation for Medical Education and Research, Rochester, MN, USA
(Prof F Alahdab MD); Research Committee, Education Committee, and
Avicenna Journal of Medicine Editor, Syrian American Medical Society,
Washington, Washington DC, USA (Prof F Alahdab MD); School of
Population and Global Health (K Alam PhD), Medical School
(Prof G J Hankey MD), University of Western Australia, Perth, WA,
Australia; Nab’a Al-Hayat Foundation for Medical Sciences and Health
Care, Iraq (A Albujeer DDS); Research School of Population Health
(Prof K A Alene MPH), National Centre for Epidemiology and
Population Health (B Calabria PhD), Australian National University,
Canberra, ACT, Australia; Public Health Research Center, New York
University Abu Dhabi, Abu Dhabi, United Arab Emirates (R Ali MPH);
University of London, Pakistan (S Ali BA); Social Determinants of
Health Research Center, Qazvin University of Medical Sciences, Qazvin,
Iran (M Alijanzadeh PhD); Department of Health Policy and
Management, Kuwait University, Safat, Kuwait (Prof S M Aljunid PhD);
International Centre for Casemix and Clinical Coding, National
University of Malaysia, Bandar Tun Razak, Malaysia
(Prof S M Aljunid PhD); Department of Population Health, Luxembourg
Institute of Health, Strassen, Luxembourg (A Alkerwi PhD); Swedish
Research Council for Health, Working Life, and Welfare, Stockholm,
Sweden (Prof P Allebeck MD); Research Group in Health Economics,
University of Cartagena, Cartagena, Colombia
(Prof N Alvis-Guzman PhD); Research Group in Hospital Management
and Health Policies, University of the Coast, Barranquilla, Colombia
(Prof N Alvis-Guzman PhD); Sansom Institute, University of South
Australia (A Amare PhD); Wardliparingga Aboriginal Research Unit
(P S Azzopardi PhD), South Australian Health and Medical Research
Institute, Adelaide, SA, Australia; Psychiatry (Prof T Mekonen MSc),
Bahir Dar University, Bahir Dar, Ethiopia (A Amare PhD); School of
Public Health (L N Aminde MD, F J Charlson PhD,
Prof B A Dachew MPH, H E Erskine PhD, A J Ferrari PhD,
D F Santomauro PhD), School of Dentistry (Prof R Lalloo PhD),
University of Queensland, Brisbane, QLD, Australia (J Leung PhD,
Prof H A Whiteford PhD); Department of the Health Industrial Complex
and Innovation in Health (Prof D A Silveira MSc), Department of
Diseases and Non-Communicable Diseases and Health Promotion
(A M Soares Filho DSc), Federal Ministry of Health, Brasilia, Brazil;
Federal Ministry of Health, Beirut, Lebanon (Prof W Ammar PhD);
Faculty of Health Sciences (Prof W Ammar PhD), Department of
Epidemiology and Population Health (Prof L A Ghandour PhD),
American University of Beirut, Beirut, Lebanon; Department of Internal
Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana
(Y A Amoako MD); Lee Kuan Yew School of Public Policy
(G G H Amul MSc), Yong Loo Lin School of Medicine
(Prof N Venketasubramanian FRCP), National University of Singapore,
Singapore, Singapore; Department of Legal Medicine and Bioethics
(Prof M Hostiuc PhD), Carol Davila University of Medicine and
Pharmacy, Bucharest, Romania (C Andrei PhD); School of Health and
Articles
www.thelancet.com Vol 392 September 22, 2018
1029
Related Research, University of Sheeld, Sheeld, UK (C Angus MSc);
Department of Health Policy and Administration (C T Antonio MD),
Development and Communication Studies (E K Macarayan PhD),
University of the Philippines Manila, Manila, Philippines; School of
Health Sciences, Birmingham City University, Birmingham, England
(O Aremu PhD); School of Health and Social Studies, Dalarna
University, Falun, Sweden (Prof J Ärnlöv PhD); Department of
Community Health Sciences, University of Manitoba, Winnipeg, MB,
Canada (A Artaman PhD); DFID Nepal Health Sector Programme 3,
Monitoring Evaluation and Operational Research Project, ABT
Associates Nepal, Lalitpur, Nepal (K K Aryal PhD); Education
Development Center (Prof R Assadi PhD), Department of Medical
Biotechnology (Prof A Sahebkar PhD), Mashhad University of Medical
Sciences, Mashhad, Iran; School of Business, University of Leicester,
Leicester, UK (Prof M Ausloos PhD); Center for Health Systems
Research (L Avila-Burgos PhD, L Cahuana-Hurtado PhD,
Prof I Heredia-Pi DipSocSc, D D V Ortega-Altamirano DrPH), National
Institute of Public Health, Cuernavaca, Mexico
(I R Campos-Nonato PhD, J Campuzano Rincon PhD, F De Castro PhD);
Deworm3 Project, Bénin Clinical Research Institute (IRCB), Calavi,
Benin (E F Avokpaho MD); Control of Infectious Diseases Project
(E F Avokpaho MD), Non-Communicable Disease Department
(F G Gankpe MD), Laboratory of Studies and Research-Action in Health
(LERAS), Porto-Novo, Benin; Indian Institute of Public Health,
Gandhinagar, India (A Awasthi PhD); Department of Epidemiology,
Biostatistics, and Occupational Health, McGill University, Montreal, QC,
Canada (H T Ayele PhD); Department of Public Health, Dilla University,
Dilla, Ethiopia (H T Ayele PhD); Department of Community and Global
Health (R Ayer MSc), Department of Mental Health
(Prof N Kawakami PhD), Department of Diabetes and Metabolic
Diseases (Prof T Yamada MD), University of Tokyo, Tokyo, Japan; Centre
for Food and Nutrition Research, Institute of Medical Research and
Plant Medicinal Studies, Yaounde, Cameroon (T B Ayuk PhD);
Department of Health Studies, University of South Africa, Pretoria,
South Africa (T B Ayuk PhD); Global Adolescent Health Group,
Maternal and Child Health Program, Discipline of International
Development, Burnet Institute, Melbourne, VIC, Australia
(P S Azzopardi PhD); Department of Medical Mycology/Invasive Fungi
Research Center (Prof H Badali PhD), Toxoplasmosis Research Center
(Prof A Daryani PhD), Molecular and Cell Biology Research Center
(Prof A Rafiei PhD), Department of Pediatrics (Prof M Rezai MD),
Department of Immunology (Prof A Rafiei PhD), Mazandaran
University of Medical Sciences, Sari, Iran; Public Health Risk Sciences
Division (A Badawi PhD), Health Promotion and Chronic Disease
Prevention Branch (J J Lang PhD), Applied Research Division
(H M Orpana PhD), Public Health Agency of Canada, Toronto, ON,
Canada; Department of Hypertension, Medical University of Lodz, Lodz,
Poland (Prof M Banach PhD); Polish Mother’s Memorial Hospital
Research Institute (PMMHRI), Lodz, Poland (Prof M Banach PhD);
School of Psychology, University of Auckland, Auckland, New Zealand
(Prof S L Barker-Collo PhD); Department of Industrial Engineering,
Pontificia Universidad Javeriana, Bogota, Colombia
(Prof L H Barrero DSc); University of Aden, Aden, Yemen
(Prof H Basaleem PhD); Department of Public Health, Wollo University,
Dessie, Ethiopia (E Baye MPH); Department of Psychiatry,
Charles R. Drew University of Medicine and Science, Los Angeles, CA,
USA (Prof S Bazargan-Hejazi BEP); Department of Psychiatry and
Biobehavioral Sciences, University of California Los Angeles,
Los Angeles, CA, USA (Prof S Bazargan-Hejazi BEP); Department of
Community Medicine, Gandhi Medical College Bhopal, Bhopal, India
(Prof N Bedi MD); Jazan University, Saudi Arabia (Prof N Bedi MD);
Department of Neurology, University Hospital of Dijon, Dijon, France
(Prof Y Béjot PhD); Dijon Stroke Registry, Faculty of Health Sciences,
University of Burgundy, Dijon, France (Prof Y Béjot PhD); School of
Public Health (A B Belachew MSc, G B Gebregergs MPH), Institute of
Biomedical Sciences, Department of Anatomy and Embryology, College
of Health Sciences (T B Hagos MS), Biomedical Sciences Division,
School of Medicine (Prof G B Hailu MSc, D T Mengistu MSc), Nutrition
and Dietetics (A Kahsay MPH), Clinical Pharmacy Unit
(T D D Kassa MSc, Y L Nirayo MSc, K G Weldegwergs MSc), School of
Pharmacy (E Yimer MSc), Mekelle University, Mekelle, Ethiopia
(Prof K G Meles MPH); Dr. Tewelde Legesse Health Sciences College,
Mekelle, Ethiopia (S A Belay MPH); Department of Internal Medicine
(I M Bensenor PhD, Prof P A Lotufo DrPH, Prof I S Santos PhD),
Center for Clinical and Epidemiological Research (A C Goulart PhD),
Department of Psychiatry (Y Wang PhD), University of São Paulo,
São Paulo, Brazil; Dental Institute (E Bernabe PhD), Faculty of Life
Sciences and Medicine (Prof P I Dargan MB), King’s College London,
London, UK; Hubert Department of Global Health, Emory University,
Atlanta, GA, USA (R S Bernstein MD); Department of Global Health,
University of South Florida, Tampa, Florida, USA (R S Bernstein MD);
School of Public Health and Medicine, University of Newcastle,
Newcastle, NSW, Australia (A S Beyene MPH, M Khan MSc); Air
Pollution Research Center (B Heibati PhD), Community Medicine
Department (Prof A Tehrani-Banihashemi PhD), Preventive Medicine
and Public Health Research Center (Prof A Tehrani-Banihashemi PhD),
Iran University of Medical Sciences, Tehran, Iran (T Beyranvand PhD);
Research (Prof P K Maulik PhD), The George Institute for Global
Health, New Delhi, India (S Bhaumik MBBS); Center of Excellence in
Women and Child Health, Aga Khan University, Karachi, Pakistan
(Prof Z A Bhutta PhD); Social Determinants of Health Research Center
(A Bijani PhD), Health Research Institute (Prof R Ghadimi PhD,
A Bijani PhD, A Rostami PhD), Department of Clinical Biochemistry
(Prof H Parsian PhD), Infectious Diseases and Tropical Medicine
Research Center (A Rostami PhD), Student Research Committee
(M Zamani MD), Babol University of Medical Sciences, Babol, Iran
(Prof M Faramarzi PhD); Woldia University, Woldia, Ethiopia
(N Bililign BHlthSci); Department of Medical and Surgical Sciences
(A Farioli PhD, Prof F S Violante MD), University of Bologna, Bologna,
Italy (S M Birlik MBA); GBS/CIDP Foundation International,
Conshohocken, PA, USA (S M Birlik MBA); The UCL Centre for Global
Health Economics (C Birungi MSc), Department of Health Informatics
(S Chung PhD), Department of Epidemiology and Public Health
(Prof M Kivimäki PhD), University College London, London, UK;
Fast-Track Implementation Department, United Nations Programme on
HIV/AIDS (UNAIDS), Gaborone, Botswana (C Birungi MSc); Public
Health, St Paul’s Hospital Millennium Medical College, Addis Ababa,
Ethiopia (H Bizuneh MPH); Department of Global Public Health and
Primary Care, University of Bergen, Bergen, Norway
(Prof T Bjørge PhD); Department of Research (Prof E Weiderpass PhD),
Cancer Registry of Norway, Oslo, Norway (Prof T Bjørge PhD);
Department of Epidemiology and Psychosocial Research, National
Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico
(Prof G Borges DSc, R A Gutiérrez PhD); Department of Oncology
(C Bosetti PhD), Department of Environmental Health Science
(S Gallus DSc), Mario Negri Institute for Pharmacological Research
(IRCCS), Milan, Italy; Transport and Road Safety (TARS) Research
(S Boufous PhD), National Drug and Alcohol Research Centre
(B Calabria PhD, Prof L Degenhardt PhD), School of Medicine
(Prof P K Maulik PhD), School of Public Health and Community
Medicine (Prof F Sitas PhD), University of New South Wales, Sydney,
NSW, Australia; University of Genoa, Italy (N L Bragazzi PhD); Division
of Clinical Epidemiology and Aging Research, German Cancer Research
Center, Heidelberg, Germany (Prof H Brenner MD, B Schöttker PhD);
School of Population and Public Health (Z A Butt PhD,
F Pourmalek PhD, Prof N Sarrafzadegan MD), University of British
Columbia, Vancouver, BC, Canada (C C Gotay PhD); Al Shifa School of
Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan
(Z A Butt PhD); School of Medicine, University of the Valley of
Cuernavaca, Cuernavaca, Mexico (J Campuzano Rincon PhD); Institute
for Cancer Research, Prevention and Clinical Network (ISPRO),
Florence, Italy (G Carreras PhD); Applied Molecular Biosciences Unit
(Prof F Carvalho PhD), Institute of Biomedical Engineering (INEB),
(J Das Neves PhD), Department of Chemistry (Prof E Fernandes PhD),
Institute for Research and Innovation in Health (i3s) (J Das Neves PhD),
University of Porto, Porto, Portugal; Colombian National Health
Observatory, National Institute of Health, Bogota, Colombia
(C A Castañeda-Orjuela MSc); Epidemiology and Public Health
Evaluation Group, National University of Colombia, Bogota, Colombia
(C A Castañeda-Orjuela MSc); Costa Rican Department of Social
Security, San Jose, Costa Rica (Prof J Castillo Rivas MSc); School of
Dentistry, University of Costa Rica, San Pedro, Costa Rica
Articles
1030
www.thelancet.com Vol 392 September 22, 2018
(Prof J Castillo Rivas MSc); Department of Health Planning and
Economics, National School of Public Health, Institute of Health Carlos
III, Madrid, Spain (F Catalá-López PhD); College of Medicine, National
Taiwan University, Taipei, Taiwan (Prof J Chang PhD); Department of
Development Studies (Prof A Chattopadhyay PhD), Department of
Public Health & Mortality Studies (Prof U Ram PhD), International
Institute for Population Sciences, Mumbai, India (P Kumar PhD,
A Patle MPH); Tata Memorial Hospital, Mumbai, India
(Prof P Chaturvedi MD); Department of Public Health and Primary Care,
University of Cambridge, UK (Prof R Chowdhury PhD); Department
of Pulmonary Medicine (Prof D J Christopher FRCP), Department of
Community Health (Prof A M Oommen MD), Department of
Endocrinology (Prof N Thomas PhD), Christian Medical College and
Hospital (CMC), Vellore, India; Health Data Research UK, London, UK
(S Chung PhD); School of Medicine (L G Ciobanu PhD), University of
Adelaide, Adelaide, SA, Australia (A T Olagunju MD); Department of
Nutrition (Prof R M Claro PhD), Department of Maternal and Child
Nursing and Public Health (Prof M S Felisbino-Mendes PhD,
Prof D C Malta PhD), School of Nursing (I E Machado PhD), Federal
University of Minas Gerais, Belo Horizonte, Brazil; Department of
Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
(S Conti PhD, A Lafranconi MD, F Madotto PhD); Postgraduate Program
in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre,
Brazil (E Cousin MSc, B B Duncan MD, Prof M I Schmidt PhD);
Department of Family Medicine and Public Health, University of
California San Diego, La Jolla, CA, USA (Prof M H Criqui MD); Clinical
Toxicology Service, Guy’s and St. Thomas’ NHS Foundation Trust,
London, UK (Prof P I Dargan MB); Kazakh National Medical University,
Almaty, Kazakhstan (Prof K Davletov PhD); Monash Centre for Health
Research and Implementation (Prof B de Courten PhD), School of
Public Health and Preventive Medicine (Prof Y Guo PhD), Centre of
Cardiovascular Research and Education in Therapeutics
(R Ofori-Asenso MSc), Monash University, Melbourne, VIC, Australia;
Monash Health, Melbourne, VIC, Australia (Prof B de Courten PhD);
Institute of Public Health (Prof J De Neve MD, B Moazen MSc,
S Mohammed PhD), Department of Ophthalmology, Medical Faculty
Mannheim (Prof J B Jonas MD), Heidelberg University, Heidelberg,
Germany; Department of Clinical Pharmacy, Aksum University, Aksum,
Ethiopia (G T Demoz MSc); Department of Psychiatry, Icahn School of
Medicine at Mount Sinai, New York, NY, USA
(Prof D C Des Jarlais PhD); Disha Foundation, Gurgaon, India
(S Dey PhD); Indian Council of Medical Research, New Delhi, India
(R S Dhaliwal MD); Department of Community Medicine, University of
Peradeniya, Peradeniya, Sri Lanka (S D Dharmaratne MD); Health
Research Section, Nepal Health Research Council, Kathmandu, Nepal
(M Dhimal PhD); Department of Population and Health, University of
Cape Coast, Cape Coast, Ghana (D T Doku PhD); School of Health
Sciences, University of Tampere, Tampere, Finland (D T Doku PhD,
S Neupane PhD); School of Health and Biomedical Sciences, Royal
Melbourne Institute of Technology (RMIT) University, Bundoora, VIC,
Australia (Prof K E Doyle PhD); United Nations World Food Programme,
New Delhi, India (M Dubey PhD); Faculty of Medicine, University of
Belgrade, Serbia (E Dubljanin PhD); Department of Clinical Pathology,
Mansoura University, Mansoura, Egypt (Prof M El Sayed Zaki PhD);
Laboratory for Socio-Economic Issues of Human Development and
Quality of Life, Russian Academy of Sciences, Moscow, Russia
(Prof S P Ermakov DSc); Department of Medical Statistics and
Documentary (Prof S P Ermakov DSc), Federal Research Institute for
Health Organization and Informatics of the Ministry of Health
(FRIHOI), Moscow, Russia (S K Vladimirov PhD); Policy and
Epidemiology Group (D F Santomauro PhD), Queensland Centre for
Mental Health Research, Brisbane, QLD, Australia (H E Erskine PhD,
A J Ferrari PhD); Department of Psychology, Federal University of
Sergipe, Sao Cristovao, Brazil (Prof A Faro PhD); National Institute for
Stroke and Applied Neurosciences, Auckland University of Technology,
Auckland, New Zealand (Prof V L Feigin PhD); Federal University of
São Paulo, São Paulo, Brazil (C P Ferri PhD); Heller School for Social
Policy and Management, Brandeis University, Waltham, MA, USA
(D O Fijabi MS); School of Public Health, University of Memphis,
Memphis, Tennessee, USA (D O Fijabi MS); Kaiser Permanente,
Fontana, CA, USA (I Filip MD); Department of Health Sciences
(I Filip MD), A.T. Still University, Mesa, Arizona, USA (A Radfar MD);
Department of Epidemiology and Health Monitoring, Robert Koch
Institute, Berlin, Germany (J D Finger PhD); Department of Public
Health Medicine, Bielefeld University, Bielefeld, Germany
(F Fischer PhD); College of Public Health, Medical and Veterinary
Science, James Cook University, Townsville, QLD, Australia
(Prof R C Franklin PhD); Neurosurgery Department, Sidi Mohamed
Ben Abdellah University, Fez, Morocco (F G Gankpe MD); Division of
Human Nutrition and Health, Wageningen University & Research,
Wageningen, Netherlands (Prof J M Geleijnse PhD); Department of
Health Care Policy & Management, University of Tsukuba, Tsukuba,
Japan (M Ghimire MA); Unit of Academic Primary Care
(Prof P S Gill DM), Division of Health Sciences (Prof O A Uthman PhD),
University of Warwick, Coventry, UK; Department of Family and
Community Medicine, University of Hail, Hail, Saudi Arabia
(Prof I A Ginawi MD); College of Nursing and Health Sciences,
University of Massachusetts Boston, Boston, MA, USA
(Prof P N Gona PhD); Department of Biostatistics and Epidemiology,
University of Oklahoma, Oklahoma City, OK, USA (S V Gopalani MPH);
Department of Health and Social Aairs, Government of the Federated
States of Micronesia, Palikir, Federated States of Micronesia
(S V Gopalani MPH); Department of Primary Care and Public Health
(F Greaves PhD, Prof A Majeed MD, Prof S Rawaf PhD), WHO
Collaborating Centre for Public Health Education & Training
(D L Rawaf MD), School of Public Health (Prof S Saxena MD), Imperial
College London, London, UK; Health Improvement Directorate
(F Greaves PhD), Public Health England, London, UK
(Prof S Rawaf PhD); Integrated Tumor Registry, University-Hospital
Polyclinic Vittorio Emanuele, Catania, Italy (G Grosso PhD);
Commissioner of Public Health, West Virginia Bureau for Public Health,
Charleston, WV, USA (Prof R Gupta MD); Department of Health Policy,
Management & Leadership, West Virginia University, Morgantown, WV,
USA (Prof R Gupta MD); Rajasthan University of Health Sciences,
Jaipur, India (Prof R Gupta MD); Department of Preventive Cardiology,
Eternal Heart Care Centre & Research Institute, Jaipur, India
(Prof R Gupta MD); Department of Anthropology, University of Delhi,
Delhi, India (V Gupta PhD); Indian Institute of Public Health, Public
Health Foundation of India, Hyderabad, Hyderabad, India
(Prof M GVS MD); Department of Radiology, Johns Hopkins University,
Baltimore, MD, USA (N Hafezi-Nejad MD); Department of Family and
Community Medicine, Arabian Gulf University, Manama, Bahrain
(Prof R R Hamadeh DPhil); School of Health and Environmental
Studies, Hamdan Bin Mohammed Smart University, Dubai, United
Arab Emirates (Prof S Hamidi DrPH); Neurology Department, Sir
Charles Gairdner Hospital, Perth, WA, Australia (Prof G J Hankey MD);
Department of Vital and Health Statistics (H L Harb MPH), Department
of Disease, Epidemics and Pandemics Control (J Nansseu MD), Ministry
of Public Health, Beirut, Lebanon; Cardiology Department
(Prof S Harikrishnan MD), Sree Chitra Tirunal Institute for Medical
Sciences and Technology, Trivandrum, India (G Mini PhD); Research
and Development Unit, Parc Sanitari Sant Joan de Déu (CIBERSAM),
Sant Boi de Llobregat, Spain (Prof J M Haro MD, A Koyanagi MD,
S Tyrovolas PhD); Department of Medicine (Prof J M Haro MD),
University of Barcelona, Barcelona, Spain (S Tyrovolas PhD); Public
Health Department (H Y Hassen MPH), Pharmacy Department
(A T Kefale MSc), Mizan-Tepi University, Mizan Teferi, Ethiopia
(Prof A Henok MPH); Unit of Epidemiology and Social Medicine,
University Hospital Antwerp, Wilrijk, Belgium (H Y Hassen MPH);
Karolinska University Hospital, Stockholm, Sweden
(R Havmoeller PhD); Subdirectorate of Regulations, Guidelines and
Technical Procedures, Secretary of Health, National Commission
Against Addiction, Mexico City, Mexico
(Prof N F Hernández-Llanes MPH); Department of Statistics and
Econometrics (Prof C Herteliu PhD, Prof A Mirica PhD, A Pana MD),
Bucharest University of Economic Studies, Bucharest, Romania
(B V Ileanu PhD); Department of Reproductive Health, Hawassa
University, Hawassa Ethiopia (D T T Hibstu MPH); Transdisciplinary
Centre for Qualitative Methods, Manipal University, Manipal, India
(P Hoogar PhD); Department of Pulmonology, Yokohama City
University, Yokohama, Japan (N Horita MD); National Human Genome
Research Institute (NHGRI), National Institutes of Health,
Articles
www.thelancet.com Vol 392 September 22, 2018
1031
Bethesda, MD, USA (N Horita MD); Department of Epidemiology and
Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
(Prof H Hosgood PhD); Department of Internal Medicine, Emergency
Hospital of Bucharest, Bucharest, Romania (Prof M Hostiuc PhD);
Department of Epidemiology and Health Statistics, Xiangya School of
Public Health, Central South University, Changsha, China
(Prof G Hu PhD); Department of Psychiatry, Cambridge Health Alliance,
Cambridge, MA, USA (H Huang MD); Institute of Community and
Public Health, Birzeit University, Birzeit, Palestine
(Prof A Husseini PhD); Qatar University, Doha, Qatar
(Prof A Husseini PhD); Infectious Diseases Department, Bashkir State
Medical University, Ufa, Russia (B Idrisov MD); Department of Public
Health and Community Medicine, University of Liberia, Monrovia,
Liberia (O S Ilesanmi PhD); Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences, Tehran, Iran
(S N Irvani MD); Institute for Physical Activity and Nutrition
(S Islam PhD), National Centre for Farmer Health, School of Medicine
(M Rahman PhD), Deakin University, Waurn Ponds, VIC, Australia;
Department of Community Health and Psychiatry, University of the
West Indies, Mona, Jamaica (Prof M D Jackson PhD); Faculty of Medical
Sciences, University of Kragujevac, Kragujevac, Serbia
(Prof M Jakovljevic PhD); Faculty of Graduate Studies
(A U Jayatilleke PhD), Postgraduate Institute of Medicine
(A U Jayatilleke PhD), University of Colombo, Colombo, Sri Lanka;
Department of Community Medicine, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India (R P Jha MSc); Capital
Medical University, Beijing Institute of Ophthalmology, Beijing, China
(Prof J B Jonas MD); Institution of Health and Nutrition Sciences,
Czestochowa University of Technology, Czestochowa, Poland
(Prof J J Jozwiak PhD); Faculty of Medicine and Health Sciences,
University of Opole, Opole, Poland (Prof J J Jozwiak PhD); School of
Public Health, University College Cork, Cork, Ireland (Z Kabir PhD);
Department of Health Policy, Personal Social Services Research Unit,
London School of Economics and Political Science, London, UK
(R Kadel MPH); A.C.S. Medical College and Hospital, New Delhi, India
(Prof U Kapil MD, Prof Z Zaidi DrPH); MRC/CSO Social & Public
Health Sciences Unit, University of Glasgow, Glasgow, UK
(S V Katikireddi PhD); Midwifery Program, Salale University, Fiche,
Ethiopia (S Kebede MSc); Odel Campus, University of Nairobi, Nairobi,
Kenya (Prof P N Keiyoro PhD); Non-Communicable Diseases Research
Unit (Prof A P Kengne PhD), Alcohol, Tobacco & Other Drug Use
Research Unit (Prof C D H Parry PhD), Medical Research Council South
Africa, Cape Town, South Africa; Department of Medicine
(Prof A P Kengne PhD, J Noubiap MD), Groote Schuur Hospital
(G A Mensah MD), Department of Psychiatry and Mental Health
(Prof D J Stein MD), University of Cape Town, Cape Town, South Africa;
Department of Public Health and Community Medicine, Jordan
University of Science and Technology, Alramtha, Jordan
(Prof Y Khader PhD); Department of Public Health
(Prof M A Khafaie PhD), Health Research Institute, Thalassemia and
Hemoglobinopathy Research Center (Prof F Rahim PhD), Ahvaz
Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of
Population Sciences, Jatiya Kabi Kazi Nazrul Islam University,
Mymensingh, Bangladesh (M Khan MSc); Institute of Health Policy and
Management, SNU Medical Research Center (Prof Y Khang MD),
Department of Health Policy and Management (Prof Y Khang MD),
Seoul National University, Seoul, South Korea; Department of Medical
Parasitology, Cairo University, Cairo, Egypt (M M Khater MD);
Department of Nutrition and Health Science, Ball State University,
Muncie, IN, USA (Prof J Khubchandani PhD); Korea Health Industry
Development Institute, Cheongju-Si, South Korea (C Kim PhD);
Department of Health Sciences, Northeastern University, Boston, MA,
USA (Prof D Kim DrPH); School of Medicine, Xiamen University
Malaysia, Sepang, Malaysia (Prof Y Kim PhD); Department of Nutrition,
Simmons College, Boston, MA, USA (R W Kimokoti MD); Department
of Health Management and Health Economics (Prof A Kisa PhD),
Norwegian Center for Addiction Research (SERAF), (S P Neupane PhD),
University of Oslo, Oslo, Norway; Department of Global Community
Health and Behavioral Sciences, Tulane University, New Orleans, LA,
USA (Prof A Kisa PhD); Department of Public Health
(Prof M Kivimäki PhD, T Lallukka PhD), University of Helsinki,
Helsinki, Finland (T J Meretoja MD); Department of Public Health,
Erasmus University Medical Center Rotterdam, The Netherlands,
Erasmus University Medical Center, Netherlands (S Kochhar MD);
International Institute of Health Management Research, New Delhi,
India (A Patle MPH); Independent Consultant, Jakarta, Indonesia
(S Kosen MD); Department of Internal and Pulmonary Medicine, Sheri
Kashmir Institute of Medical Sciences, Srinagar, India
(Prof P A Koul MD); Department of Anthropology, Panjab University,
Chandigarh, India (Prof K Krishan PhD); Department of Social and
Preventive Medicine (Prof B Kuate Defo PhD), Department of
Demography (Prof B Kuate Defo PhD), University of Montreal,
Montreal, QC, Canada; Faculty of Medicine, Department of Public
Health, Yuksek Ihtisas University, Ankara, Turkey
(Prof B Kucuk Bicer BEP); Faculty of Medicine, Department of Public
Health, Hacettepe University, Ankara, Turkey (Prof B Kucuk Bicer BEP);
Arkansas State University, USA (V S Kulkarni PhD); Department of
Paediatrics (Prof G C Patton MD), Australian Institute of Muscular
Skeletal Sciences, Department of Medicine and Neurology
(Prof T Wijeratne MD), University of Melbourne, Melbourne, VIC,
Australia; Department of Community Medicine (M S Nayak MD),
Rajiv Gandhi University of Health Sciences, Bangalore, India
(A Lakshmana Balaji MPH); Population and Work Ability Program
(T Lallukka PhD), Finnish Institute of Occupational Health, Helsinki,
Finland (R Shiri PhD); Institute of Health Policy and Development
Studies, National Institutes of Health, Manila, Philippines
(Prof H Lam PhD); Department of Community and Family Medicine
(Prof F H Lami PhD), Academy of Medical Science, Baghdad, Iraq;
Division of Cancer Epidemiology & Genetics, National Cancer Institute,
Rockville, MD, USA (Q Lan PhD); Belo Horizonte City Hall, Municipal
Health Department of Belo Horizonte, Belo Horizonte, Brazil
(Prof S Lansky PhD); Department of Medical Sciences, Uppsala
University, Uppsala, Sweden (Prof A O Larsson PhD); Department of
Clinical Chemistry and Pharmacology, Akademiska Sjukhuset, Uppsala,
Sweden (Prof A O Larsson PhD); Managerial Epidemiology Research
Center, Department of Public Health, School of Nursing and Midwifery
(S Safiri PhD), Department of Public Health, School of Public Health,
(A Latifi PhD), Maragheh University of Medical Sciences, Maragheh,
Iran; College of Optometry, Nova Southeastern University, Fort
Lauderdale, FL, USA (J L Leasher OD); School of Nursing, Hong Kong
Polytechnic University, Hong Kong, China (P H Lee PhD); Asbestos
Diseases Research Institute (J Leigh MD), School of Public Health
(Prof F Sitas PhD), University of Sydney, Sydney, NSW, Australia;
Scohost, Södertörn University, Huddinge, Sweden
(Prof M Leinsalu PhD); Department of Epidemiology and Biostatistics,
National Institute for Health Development, Tallinn, Estonia
(Prof M Leinsalu PhD); CERIMP, Local Health Unit Tuscany Centre,
Florence, Italy (M Levi PhD); Department of Health Sciences, University
of Florence, Florence, Italy (M Levi PhD); Department of Clinical and
Epidemiological Research, Shenzen Institute of Cardiovascular Disease,
Shenzhen, China (Prof Y Li PhD); Department of Medicine, University
of Malaya, Kuala Lumpur, Malaysia (L Lim MRCP); Department of
Medicine and Therapeutics, The Chinese University of Hong Kong,
Shatin, China (L Lim MRCP); School of Public Health, University of
Haifa, Haifa, Israel (Prof S Linn DrPH); Centre for Chronic Disease
Control, China (Prof S Liu PhD); National Institute of Energy Eciency
and Renewable Energies (INER), Quito, Ecuador
(A Lobato-Cordero MSc); Damietta University, Damietta, Egypt
(H Magdy Abd El Razek MD); Opthamology Department, Aswan Faculty
of Medicine, Aswan, Egypt (M Magdy Abd El Razek MB); Department of
Public Health, Trnava University, Trnava, Slovakia (Prof M Majdan PhD);
Non-Communicable Diseases Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran (Prof R Malekzadeh MD,
S G Sepanlou MD); Department of Population Studies, University of
Zambia, Lusaka, Zambia (C Mapoma PhD); Psychiatry Department,
Doctor Peset University Hospital, Valencia, Spain (J Martinez-Raga MD);
Department of Medicine (J Martinez-Raga MD,
Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain;
Department of Biology and Biological Engineering, Chalmers University
of Technology, Gothenburg, Sweden (M Mazidi PhD); Department of
Health Services Research & Policy (Prof M McKee DSc), Department of
Non-communicable Disease Epidemiology (Prof D Prabhakaran DM),
Articles
1032
www.thelancet.com Vol 392 September 22, 2018
London School of Hygiene & Tropical Medicine, London, UK;
Department of Internal Medicine, Sevenhills Hospital, Mumbai, India
(V Mehta MD); Institute for Agricultural and Nutritional Sciences
(T Meier PhD), Institute of Epidemiology, Biostatistics and Informatics
(I Shiue PhD), Martin Luther University Halle-Wittenberg, Halle,
Germany; Innovation Oce Nutricard, Competence Cluster for
Nutrition and Cardiovascular Health (NUTRICARD), Halle, Germany
(T Meier PhD); College of Health Sciences, Debre Tabor University,
Debre Tabor, Ethiopia (A Melese MSc); Department of Public Health,
University of West Florida, Pensacola, FL, USA
(Prof P T N Memiah DrPH); Peru Country Oce of the UNFPA, United
Nations Population Fund (UNFPA), Lima, Peru (W Mendoza MD);
Center for Translation Research and Implementation Science, National
Heart, Lung, and Blood Institute, Bethesda, MD, USA
(G A Mensah MD); Comprehensive Cancer Center, Breast Surgery Unit,
Helsinki University Hospital, Helsinki, Finland (T J Meretoja MD);
Ethiopian Academy of Medical Science, Mekelle, Ethiopia
(Prof H B Mezgebe MSc); Department of Hypertension & Internal
Medicine (Prof T Miazgowski MD), Zdroje Hospital (J Widecka PhD),
Pomeranian Medical University, Szczecin, Poland; Pacific Institute for
Research & Evaluation, Calverton, MD, USA (T R Miller PhD); School of
Public Health, Curtin University, Perth, WA, Australia (T R Miller PhD);
Department of Public Health, Amrita Institute of Medical Sciences,
Kochi, India (G Mini PhD); President’s Oce, National Institute of
Statistics Romania, Bucharest, Romania (Prof A Mirica PhD); Kyrgyz
State Medical Academy, Bishkek, Kyrgyzstan
(Prof E M Mirrakhimov MD); Department of Atherosclerosis and
Coronary Heart Disease, National Center of Cardiology and Internal
Disease, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov MD); Department
of Health and Social Work, Institute of Addiction Research (ISFF),
Frankfurt University of Applied Sciences, Frankfurt Am Main, Germany
(B Moazen MSc); Department of Biology, Salahaddin University, Erbil,
Iraq (K A Mohammad PhD); Nutrition and Cohort Studies Department,
Isfahan Cardiovascular Research Institute (N Mohammadifard PhD),
Cardiovascular Research Institute (Prof N Sarrafzadegan MD), Isfahan
University of Medical Sciences, Isfahan, Iran; Health Systems and Policy
Research Unit (S Mohammed PhD), Department of Community
Medicine (M B Sufiyan MD), Ahmadu Bello University, Zaria, Nigeria;
Clinical Epidemiology and Public Health Research Unit, Institute for
Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy
(L Monasta DSc, L Ronfani PhD); Lancaster University, UK
(P Moraga PhD); International Laboratory for Air Quality and Health,
Science and Engineering Faculty, Queensland University of Technology,
Brisbane, QLD, Australia (Prof L Morawska PhD); St. Paul’s Hospital
Millennium Medical College, Addis Ababa, Ethiopia (M T Jalu MPH);
Department of Endocrinology & Metabolism, Institute of Postgraduate
Medical Education and Research, Kolkata, Kolkata, India
(Prof S Mukhopadhyay MD); School of Medical Sciences, University
Sains Malaysia, Kubang Kerian, Malaysia (Prof K Musa PhD); Initiative
for Non Communicable Diseases, International Centre for Diarrhoeal
Disease Research, Bangladesh, Dhaka, Bangladesh (A Naheed PhD);
Department of Epidemiology, University of Alabama at Birmingham,
Birmingham, AL, USA (G Naik MPH); Epidemiology Department
(Prof F Najafi PhD), Research Center for Environmental Determinants
of Health (M Soofi PhD), Kermanshah University of Medical Sciences,
Kermanshah, Iran; Suraj Eye Institute, Nagpur, India (V Nangia MD);
Department of Public Heath, Faculty of Medicine and Biomedical
Sciences, University of Yaoundé, Yaoundé, Cameroon (J Nansseu MD);
Department of Epidemiology and Public Health, University Sidi
Mohammed Ben Abdellah, Fez, Morocco (Prof C Nejjari PhD);
International School of Public Health, Mohammed Vi University of
Health Science, Casablanca, Morocco (Prof C Nejjari PhD); Norwegian
National Advisory Unit on Concurrent Substance Abuse and Mental
Health Disorders, Innlandet Hospital Trust, Brumunddal, Norway
(S P Neupane PhD); Department of Biological Sciences, University of
Embu, Embu, Kenya (J W Ngunjiri DrPH); Institute for Global Health
Innovations, Duy Tan University, Hanoi, Vietnam (C T Nguyen MPH,
L H Nguyen MPH, T H Nguyen BMedSc); Public Health Department,
Semarang State University, Kota Semarang, Indonesia
(D N A Ningrum MPH); Graduate Institute of Biomedical Informatics,
Taipei Medical University, Taipei City, Taiwan (D N A Ningrum MPH);
Research Unit, Health Policy Consult, Accra, Ghana
(R Ofori-Asenso MSc); School of Social Sciences and Psychology
Department (Prof A M N Renzaho PhD), Western Sydney University,
Penrith, NSW, Australia (F A Ogbo PhD); Dept. of Preventive Medicine,
School of Medicine, Kyung Hee University, Dongdaemun-Gu, South
Korea (Prof I Oh PhD); HIV/AIDS, STIs & TB (HAST) Programme,
Human Sciences Research Council (HSRC), Durban, South Africa
(O Oladimeji MD); School of Public Health, Faculty of Health Sciences,
University of Namibia, Osakhati, Namibia (O Oladimeji MD);
Department of Psychiatry, University of Lagos, Lagos, Nigeria
(A T Olagunju MD); Autonomous University of Chile, Chile
(Prof P R Olivares PhD); Executive Director (B O Olusanya PhD), Centre
for Healthy Start Initiative, Ikoyi, Nigeria (J O Olusanya MBA); Graduate
School of Public Health, San Diego State University, San Diego, CA,
USA (Prof E Oren PhD); School of Psychology, University of Ottawa,
Ottawa, ON, Canada (H M Orpana PhD); Center for Vaccine
Development, University of Maryland, Baltimore, MD, USA
(Prof J R Ortiz MD); Global Health Nursing, St. Luke’s International
University, Chuo-Ku, Japan (Prof E Ota PhD); College of Medicine,
University of Ibadan, Ibadan, Nigeria (Prof M O Owolabi DrM);
Agricultural Economics Group (Prof A S Oyekale PhD), Hypertension in
Africa Research Team (HART), (Prof A E Schutte PhD), North-West
University, Mafikeng, South Africa; Department of TB and Respiratory
Medicine, Jagadguru Sri Shivarathreeswara University, Mysore, India
(Prof M P A DNB); Center for Health Outcomes & Evaluation,
Bucharest, Romania (A Pana MD); Department of Medical Humanities
and Social Medicine, Kosin University, Busan, South Korea
(Prof E Park PhD); Population Health Group, Murdoch Children’s
Research Institute, Melbourne, VIC, Australia (Prof G C Patton MD);
Health, Nutrition and HIV AIDS Program, Save the Children,
Kathmandu, Nepal (D Paudel PhD); Center for International Health,
Ludwig Maximilians University, Munich, Germany (D Paudel PhD);
Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
(Prof M Petzold PhD); School of Public Health, University of
Witwatersrand, Johannesburg, South Africa (Prof M Petzold PhD);
Shanghai Mental Health Center, Shanghai Jiao Tong University,
Shanghai, China (Prof M R Phillips MD); Basic Medical Sciences
Department, Durban University of Technology, Durban, South Africa
(Prof J D Pillay PhD); Department of Economics & Business
(Prof M J Postma PhD), University Medical Center Groningen
(Prof J F M Van Boven PhD, Prof M J Postma PhD), University of
Groningen, Groningen, Netherlands; Non-Communicable Diseases
Research Center, Alborz University of Medical Sciences, Karaj, Iran
(M Qorbani PhD); Medichem, Spain (A Radfar MD); Contech School of
Public Health, Lahore, Pakistan (A Rafay MS, Prof S M Rana PhD);
Research and Evaluation Division, BRAC, Dhaka, Bangladesh
(M Rahman PhD); Austin Clinical School of Nursing (M Rahman PhD),
Centre for Alcohol Policy Research (Prof R Room PhD), Department of
Psychology and Counselling (Prof T Wijeratne MD), La Trobe University,
Heidelberg, VIC, Australia; Society for Health and Demographic
Surveillance, Suri, India (R Rai MPH); Department of Economics,
University of Göttingen, Göttingen, Germany (R Rai MPH); Medical
University Innsbruck, Austria (S Rajsic MD); Department of Nephrology,
Nizam’s Institute of Medical Sciences, Hyderabad, India
(Prof S Raju MD); Public Health Department, University of Health
Sciences, Lahore, Pakistan (Prof S M Rana PhD); Institute for Poverty
Alleviation and International Development (C L Ranabhat PhD), Yonsei
University, Nepal; University College London Hospitals, UK
(D L Rawaf MD); Department of Preventive Medicine and Occupational
Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA
(C Reis MD); Department of Clinical Research, University of Uberlândia,
Uberlândia, Brazil (L Roever PhD); Centre for Social Research on
Alcohol and Drugs, Department of Public Health Science, Stockholm
University, Stockholm, Sweden (Prof R Room PhD); Golestan Research
Center of Gastroenterology and Hepatology, Golestan University of
Medical Sciences, Gorgan, Iran (G Roshandel PhD); Department of
Cardiology, All India Institute of Medical Sciences (AIIMS), New Delhi,
India (Prof A Roy MD); National Institute for Research in Environmental
Health, Indian Council of Medical Research, Bhopal, India
(Y D Sabde MD); College of Medicine, University of Sharjah, Sharjah,
United Arab Emirates (Prof B Saddik PhD); Punjab University College
Articles
www.thelancet.com Vol 392 September 22, 2018
1033
of Pharmacy, Pakistan (Z Saleem PharmD); Center for Health Policy &
Center for Primary Care and Outcomes Research, Stanford University,
Stanford, CA, USA (Prof J A Salomon PhD); Clinical Research Division,
Chest Research Foundation, Pune, India (Prof S S Salvi MD);
Department of Surgery, Marshall University, Huntington, WV, USA
(Prof J Sanabria MD); Department of Nutrition and Preventive Medicine,
Case Western Reserve University, Cleveland, OH, USA
(Prof J Sanabria MD); Nephrology Group, LIS-Fundación Jimenez Diaz,
Madrid, Spain (M Sanchez-Niño PhD); Faculty of Medicine, Institute of
Social Medicine, Centre School of Public Health and Health
Management, University of Belgrade, Belgrade, Serbia
(Prof M M M Santric Milicevic PhD); Health Economics and Financing
Research Group, International Centre for Diarrhoeal Disease Research,
Bangladesh, Dhaka, Bangladesh (A R Sarker MSc); Department of
Health and Society, Faculty of Medicine, University of Applied and
Environmental Sciences, Bogotá, Colombia
(Prof R Sarmiento-Suárez MPH); Department of Public Health
Medicine, Howard College Campus, University of Kwazulu-Natal,
Durban, South Africa (Prof B Sartorius PhD); UGC Centre of Advanced
Study in Psychology, Utkal University, Bhubaneswar, India
(Prof M Satpathy PhD); Udyam-Global Association for Sustainable
Development, Bhubaneswar, India (Prof M Satpathy PhD); Department
of Public Health Sciences, University of North Carolina at Charlotte,
Charlotte, NC, USA (M Sawhney PhD); Market Access, Bayer, Istanbul,
Turkey (M Saylan MD); Swiss Research Institute for Public Health and
Addiction, University of Zürich, Zürich, Switzerland (M P Schaub PhD);
Health Sciences Department, Federal University of Santa Catarina,
Florianopolis, Brazil (Prof I J C Schneider PhD, Prof D A S Silva PhD);
Department of Operative and Preventive Dentistry, Charity University
Medical Center - Berlin, Berlin, Germany (Prof F Schwendicke MPH);
Independent Consultant, Karachi, Pakistan (M A A Shaikh MD);
Department of Laboratory Sciences (Prof M Sharif PhD), Department of
Basic Sciences (Prof M Sharif PhD), Islamic Azad University, Sari, Iran;
Department of Pulmonary Medicine, Fudan University, Shanghai, China
(J She MD); Usher Institute of Population Health Sciences and
Informatics, University of Edinburgh, Edinburgh, UK
(Prof A Sheikh MSc); The Research Institute at Nationwide Children’s
Hospital, Columbus, OH, USA (J Shen PhD); National Institute of
Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Washington
State University, Pullman, WA, USA (Prof K Shishani PhD); Symbiosis
Institute of Health Sciences, Symbiosis International University, Pune,
India (Prof S R Shukla PhD); Department of Psychology, Reykjavik
University, Reykjavik, Iceland (Prof I D Sigfusdottir PhD); Department
of Health and Behavior Studies, Columbia University, New York,
New York, USA (Prof I D Sigfusdottir PhD); Portuguese Institute of
Sport and Youth, Lisbon, Portugal (N T da Silva MPsych); Brasília
University, Brasília, Brazil (Prof D A Silveira MSc); School of Preventive
Oncology, Patna, India (D N N Sinha PhD); Department of
Epidemiology, Healis Sekhsaria Institute for Public Health, Mumbai,
India (D N N Sinha PhD); Pneumology Service, Research Institute of the
University Hospital of the Princess (IISP), Madrid, Spain
(Prof J B Soriano MD); Pneumology Service, Autonomous University of
Madrid, Madrid, Spain (Prof J B Soriano MD); Division of Community
Medicine, International Medical University, Kuala Lumpur, Malaysia
(Prof C T Sreeramareddy MD); Institute and Outpatient Clinic for
Occupational, Social and Environmental Medicine, University Hospital
Munich, Munich, Germany (N Steckling DrPH); Department of Public
Health, Health Services Research and Health Technology Assessment,
University for Health Sciences, Medical Informatics and Technology,
Hall I.T., Austria (N Steckling DrPH); Department of Criminology,
Law and Society, University of California Irvine, Irvine, CA, USA
(Prof B L Sykes PhD); Carlos III Health Institute, CIBERSAM, Madrid,
Spain (Prof R Tabarés-Seisdedos PhD); Cancer Control Center, Osaka
International Cancer Institute, Osaka, Japan (T Tabuchi MD);
Department of Psychiatry and Behavioral Sciences, New York Medical
College, Valhalla, NY, USA (M Tavakkoli MD); Institute of Public Health,
Jagiellonian University Medical College, Krakow, Poland
(R Topor-Madry PhD); Department of Ophthalmology, Medical School,
Aristotle University of Thessaloniki, Thessaloniki, Greece
(Prof F Topouzis PhD); Department of Health Economics, Hanoi
Medical University, Hanoi, Vietnam (Prof B X Tran PhD); Department of
Neurology, University of Copenhagen, Copenhagen, Denmark
(T C Truelsen PhD); Department of Vascular Medicine, University Heart
Center of Hamburg, Hamburg, Germany (Prof N Tsilimparis PhD);
Department of Internal Medicine, Federal Teaching Hospital, Abakaliki,
Nigeria (K N Ukwaja MSc); Gomal Centre of Biochemistry and
Biotechnology, Gomal University, Dera Ismail Khan, Pakistan
(I Ullah PhD); Programmatic Management of Drug Resistant TB Unit,
TB Culture Laboratory, Mufti Mehmood Memorial Teaching Hospital,
Dera Ismail Khan, Pakistan (I Ullah PhD); Argentine Society of
Medicine, Buenos Aires, Argentina (Prof P R Valdez MEd); Intensive
Care Unit, Hospital Velez Sarsfield, Buenos Aires, Argentina
(Prof P R Valdez MEd); UKK Institute, Tampere, Finland
(Prof T J Vasankari MD); Raes Neuroscience Centre, Raes Hospital,
Singapore, Singapore (Prof N Venketasubramanian FRCP); Department
of Information and Internet Technologies, I.M. Sechenov First Moscow
State Medical University, Moscow, Russia (S K Vladimirov PhD);
Department of Health Care Administration and Economy, National
Research University Higher School of Economics, Moscow, Russia
(Prof V Vlassov MD); Center for Disease Burden, Norwegian Institute of
Public Health, Bergen, Norway (Prof S Vollset DrPH); Department of
Nursing, Debre Markos University, Debremarkos, Ethiopia
(F W S Wagnew MSc); Foundation University Medical College,
Foundation University, Rawalpindi, Pakistan (Prof Y Waheed PhD);
Demographic Change and Ageing Research Area (A Werdecker PhD),
Competence Center of Mortality-Follow-Up, German National Cohort
(R Westerman DSc), Federal Institute for Population Research,
Wiesbaden, Germany; Independent Consultant, Satufenberg, Germany
(A Werdecker PhD); Information Services Division, NHS Scotland,
Edinburgh, Scotland (G M A Wyper MSc); University of Strathclyde,
Glasgow, Scotland (G M A Wyper MSc); School of Medicine, Nanjing
University, Nanjing, China (Prof G Xu MD); Department of Preventive
Medicine, University of Mississippi Medical Center, Jackson, MS, USA
(Prof Y Yano MD); Division of Injury Prevention and Mental Health
Improvement, Chinese Center for Disease Control and Prevention,
Beijing, China (P Ye MPH); Centre for Suicide Research and Prevention,
University of Hong Kong, Hong Kong, China (Prof P Yip PhD);
University of South Australia, Adelaide, Australia (B D Yirsaw PhD);
Department of Biostatistics, School of Public Health, Kyoto University,
Kyoto, Japan (Prof N Yonemoto MPH); Department of Preventive
Medicine, Korea University, Seoul, South Korea (Prof S Yoon PhD);
College of Public Health, Ohio State University, Columbus, OH, USA
(Prof M Yotebieng PhD); School of Public Health, University of
Kinshasa, Kinshasa, Democratic Republic of the Congo
(Prof M Yotebieng PhD); Department of Health Policy and Management,
Jackson State University, Jackson, MS, USA (Prof M Z Younis DrPH);
Tsinghua University, Beijing, China (Prof M Z Younis DrPH);
Department of Cardiology, Mother Hospital, Thrissur, India
(G Zachariah MD); University of Texas, Houston, TX, USA
(X Zhang PhD).
Contributors
Max G Griswold, Nancy Fullman, and Emmanuela Gakidou prepared
the manuscript. Max G Griswold, Nancy Fullman, and
Stephanie R M Zimsen extracted data. Max G Griswold developed the
models, methods, conducted all analysis and produced the results.
Emmanuela Gakidou, Mohammad H Forouzanfar, and
Christopher J L Murray conceived of the study. Emmanuela Gakidou
provided overall guidance. Caitlin Hawley and Joseph S Salama
managed the project. All other authors contributed to at least one of the
following: provided data, reviewed results, developed modelling
infrastructure, and/or reviewed and contributed to the final manuscript.
Declaration of interests
Yannick Béjot reports grants and personal fees from AstraZeneca,
personal fees from Daiichi-Sankyo, personal fees from Pfizer, personal
fees from MSD, personal fees from Medtronic, personal fees from
BMS, personal fees from Amgen, grants and personal fees from
Boehringer-Ingelheim, outside the submitted work. Jacek Jóźwiak
reports grants and personal fees from VALEANT, personal fees from
ALAB Laboratoria, personal fees from AMGEN, non-financial support
from MICROLIFE, non-financial support from SERVIER, outside the
submitted work. Srinivasa Vittal Katikireddi reports grants from
Articles
1034
www.thelancet.com Vol 392 September 22, 2018
Medical Research Council, grants from Scottish Government Chief
Scientist Oce, grants from NRS Senior Clinical Fellowship, during the
conduct of the study. Ted Miller reports other support from AB InBev
Foundation (ABIF), outside the submitted work. Maarten Postma
reports grants and personal fees from Sigma Tau, grants and personal
fees from MSD, grants and personal fees from GSK, grants and
personal fees from Pfizer, grants from Mundipharma, grants and
personal fees from Boehringer Ingelheim, grants and personal fees
from Novavax, grants and personal fees from Ingress Health, personal
fees from Quintiles, grants from Bayer, grants from BMS, grants and
personal fees from AbbVie, grants from Astra Zeneca, grants and
personal fees from Sanofi, personal fees from Astellas, personal fees
from Mapi, personal fees from OptumInsight, grants from ARTEG,
grants and personal fees from AscA, personal fees from Novartis,
personal fees from Swedish Orphan, personal fees from Innoval,
personal fees from Jansen, personal fees from Intercept, personal fees
from Pharmerit, other support from Ingress Health, other support from
PAG Ltd, outside the submitted work. Dan Stein reports personal fees
from LUNDBECK, personal fees from NOVARTIS, personal fees from
AMBRF, grants from NRGF, grants from SERVIER, grants from
BIOCODEX, grants from MRC, personal fees from CIPLA, personal
fees from SUN, outside the submitted work. All other authors declare
no competing interests.
Acknowledgments
Research reported in this publication was supported by the National
Institute on Aging of the National Institutes of Health under Award
Number P30AG047845. The content is solely the responsibility of the
authors and does not necessarily represent the ocial views of the
National Institutes of Health. Syed Mohamed Aljunid acknowledges
the International Centre for Casemix and Clinical Coding, Faculty of
Medicine, National University of Malaysia and Department of Health
Policy and Management, Faculty of Public Health, Kuwait University
for the approval and support to participate in this research project.
Ashish Awasthi acknowledges funding support from Department of
Science and Technology, Government of India through INSPIRE
Faculty scheme. Tambe Betran Ayuk acknowledges the Institute of
Medical Research and Medicinal Plant studies for institutional
support. Peter Azzopardi is supported by a NHMRC Early Career
Fellowship. Alaa Badawi is supported by the Public Health Agency of
Canada. Shahrzad Bazargan-Hejazi was supported by NIH National
Center for Advancing Translational Science (NCATS) UCLA CTSI
Grant Number UL1TR001881. Juan J Carrero acknowledges support
from the Swedish Heart and Lung Foundation. Felix Carvalho
acknowledges the support of the European Union (FEDER funds
POCI/01/0145/FEDER/007728 and POCI/01/0145/FEDER/007265) and
National Funds (FCT/MEC, Fundação para a Ciência e a Tecnologia
and Ministério da Educação e Ciência) under the Partnership
Agreements PT2020 UID/MULTI/04378/2013 and PT2020 UID/
QUI/50006/2013. Sheng-Chia Chung is supported by the MRC
Population Health Scientist Fellowship (MR/M015084/1). José das
Neves was supported in his contribution to this work by a Fellowship
from Fundação para a Ciência e a Tecnologia, Portugal (SFRH/
BPD/92934/2013). Jan-Walter De Neve was supported by the
Alexander von Humboldt Foundation. Louisa Degenhardt is supported
by an Australian National Health and Medical Research Council Senior
Principal Research Fellowship (IDs: 1041472, 1135991); the National
Drug and Alcohol Research Centre at the University of NSW is
supported by funding from the Australian Government under the
Substance Misuse Prevention and Service Improvements Grant Fund.
Yuming Guo was supported by the Career Development Fellowship of
Australian National Health and Medical Research Council
(#APP1107107). Praveen Hoogar would like to acknowledge the
Department of Studies in Anthropology, Karnatak University, Dharwad
and Transdisciplinary Centre for Qualitative Methods, Prasanna
School of Public Health, Manipal Academy of Higher Education,
Manipal. Shariful Islam is funded by a Senior Fellowship from
Institute for Physical Activity and Nutrition (IPAN), Deakin University
and received career transition grants from High Blood Pressure
Research Council of Australia. Mihajlo Jakovljevic would like to
acknowledge that the South-East European part of this
GBD Contribution was co-financed with the Serbian Ministry of
Education Science and Technological Development Grant OI 175 014.
Srinivasa Vittal Katikireddi acknowledges funding from an NHS
Research Scotland Senior Clinical Fellowship (SCAF/15/02), the
Medical Research Council (MC_UU_12017/13 and MC_UU_12017/15),
and the Scottish Government Chief Scientist Oce (SPHSU13 and
SPHSU15). Ai Koyanagi’s work is supported by the Miguel Servet
contract financed by the CP13/00150 and PI15/00862 projects,
integrated into the National R + D + I and funded by the ISCIII -
General Branch Evaluation and Promotion of Health Research - and
the European Regional Development Fund (ERDF-FEDER). Kewal
Krishan is supported by DST PURSE Grant and UGC Centre of
Advanced Study (CAS) awarded to the Department of Anthropology,
Panjab University, Chandigarh, India. Tea Lallukka is supported by the
Academy of Finland (Grants #287488 and #294096). Miriam Levi
acknowledges the institutional support received from CeRIMP,
Regional Centre for Occupational Diseases and Injuries, Local Health
Unit Tuscany Center, Florence, Italy. Andrea Lobato-Cordero
acknowledges the Instituto Nacional de Eficiencia Energética y
Energías Renovables (INER), Ecuador. Isis Machado acknowledges the
Brazilian National Council for Scientific and Technological
Development (CNPq) for Post-doc scholarship. Azeem Majeed
acknowledges support of Imperial College London from the
NW London NIHR Collaboration for Leadership in Applied Health
Research & Care. Toni Meier acknowledges funding from the German
Federal Ministry of Education and Research (nutriCARD, Grant
agreement number 01EA1411C). Walter Mendoza is Program Analyst
Population and Development at the Peru Country Oce of the United
Nations Population Fund-UNFPA, which does not necessarily endorse
this study. Sudan Prasad Neupane acknowledges the Southeastern
Norway Regional Health Authority [grant number 2016082].
Dr Oladimeji is an African Research Fellow hosted by Human
Sciences Research Council (HSRC), South Africa and also has
honorary aliations with Walter Sisulu University (WSU), Eastern
Cape, South Africa and School of Public Health, University of Namibia
(UNAM), Namibia. Mayowa Owolabi is supported by SIREN grant
(U54 HG007479) for investigation of risk factors of stroke (including
alcohol). Charles Parry acknowledges institutional support from the
South African Medical Research Council. Maria Dolores Sanchez-Niño
was funded by Instituto de Salud Carlos III (Miguel Servet
CP14/00133). Rodrigo Sarmiento-Suárez receives institutional support
from Universidad de Ciencias Aplicadas y Ambientales UDCA,
Bogotá, Colombia. Mete Saylan is an employee of Bayer AG.
Aletta Schutte was supported by the South African Medical Research
Council, and the National Research Foundation (SARChI Research
Chair). Aziz Sheikh is supported by The Farr Institute and Health Data
Research UK. Nadine Steckling acknowledges funding from the
European Union’s Seventh Programme for research, technological
development, and demonstration under Grant Agreement No. 603946
(Health and Environment-wide Associations based on Large
population Surveys, HEALS). Rafael Tabarés-Seisdedos was supported
in part by grant number PROMETEOII/2015/021 from Generalitat
Valenciana and the national grant PI17/00719 from ISCIII-FEDER.
Stefanos Tyrovolas was supported by the Foundation for Education and
European Culture (IPEP), the Sara Borrell postdoctoral program
(reference no. CD15/00019 from the Instituto de Salud Carlos III
(ISCIII—Spain) and the Fondos Europeo de Desarrollo Regional
(FEDER). Job FM van Boven was funded by the Department of Clinical
Pharmacy & Pharmacology, University Medical Center Groningen,
University of Groningen, The Netherlands. Harvey Whiteford is
supported by the Queensland Centre for Mental Health Research at
the University of Queensland, Brisbane, Australia.
References
1 Ezzati M, Hoorn SV, Lopez AD, et al. Comparative quantification of
mortality and burden of disease attributable to selected risk factors.
In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, eds.
Global burden of disease and risk factors. Washington (DC): World
Bank, 2006.
2 Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos CT.
The relationship of average volume of alcohol consumption and
patterns of drinking to burden of disease: an overview. Addiction
2003; 98: 1209–28.
Articles
www.thelancet.com Vol 392 September 22, 2018
1035
3 Rehm J, Room R, Monteiro M, et al. Alcohol as a risk factor for
global burden of disease. Eur Addict Res 2003; 9: 157–64.
4 Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA.
Association of alcohol consumption with selected cardiovascular
disease outcomes: a systematic review and meta-analysis. BMJ 2011;
342: d671.
5 De Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L,
de Gaetano G. Alcohol dosing and total mortality in men and
women: an updated meta-analysis of 34 prospective studies.
Arch Intern Med 2006; 166: 2437–45.
6 Howard AA, Arnsten JH, Gourevitch MN. Eect of alcohol
consumption on diabetes mellitus: a systematic review.
Ann Intern Med 2004; 140: 211.
7 Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol
and cardiovascular disease: Mendelian randomisation analysis
based on individual participant data. BMJ 2014; 349: g4164.
8 Fillmore KM, Kerr WC, Stockwell T, Chikritzhs T, Bostrom A.
Moderate alcohol use and reduced mortality risk: systematic error
in prospective studies. Addict Res Theory 2006; 14: 101–32.
9 Naimi TS, Brown DW, Brewer RD, et al. Cardiovascular risk factors
and confounders among nondrinking and moderate-drinking U.S.
adults. Am J Prev Med 2005; 28: 369–73.
10 Chikritzhs T, Stockwell T, Naimi T, Andreasson S, Dangardt F,
Liang W. Has the leaning tower of presumed health benefits from
‘moderate’ alcohol use finally collapsed? Addiction 2015; 110: 726–27.
11 Forouzanfar MH, Alexander L, Anderson HR, et al.
Global, regional, and national comparative risk assessment of
79 behavioural, environmental and occupational, and metabolic
risks or clusters of risks in 188 countries, 1990–2013: a systematic
analysis for the Global Burden of Disease Study 2013. Lancet 2015;
386: 2287–323.
12 Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990–2010: a systematic analysis for
the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–60.
13 WHO. Global status report on alcohol and health 2014.
Geneva: World Health Organization, 2014.
14 Knott CS, Coombs N, Stamatakis E, Biddulph JP. All cause
mortality and the case for age specific alcohol consumption
guidelines: pooled analyses of up to 10 population based cohorts.
BMJ 2015; 350: h384.
15 Fekjaer HO. Alcohol—a universal preventive agent? A critical
analysis. Addiction 2013; 108: 2051–57.
16 Britton A, Bell S. The protective eects of moderate drinking: lies,
damned lies, and… selection biases? Addiction 2017; 112: 218–19.
17 Naimi TS, Stockwell T, Zhao J, et al. Selection biases in
observational studies aect associations between ‘moderate’ alcohol
consumption and mortality. Addiction 2017; 112: 207–14.
18 Rehm J, Kehoe T, Gmel G, Stinson F, Grant B, Gmel G. Statistical
modeling of volume of alcohol exposure for epidemiological studies
of population health: the US example. Popul Health Metr 2010; 8: 3.
19 Nelson DE, Naimi TS, Brewer RD, Roeber J. US state alcohol sales
compared to survey data, 1993–2006. Addiction 2010; 105: 1589–96.
20 Gakidou E, Afshin A, Abajobir AA, et al. Global, regional,
and national comparative risk assessment of 84 behavioural,
environmental and occupational, and metabolic risks or clusters of
risks, 1990–2016: a systematic analysis for the Global Burden of
Disease Study 2016. Lancet 2017; 390: 1345–422.
21 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and
transparent health estimates reporting: the GATHER statement.
Lancet 2016; 388: e19–23.
22 Hill AB. The environment and disease: association or causation?
Proc R Soc Med 1965; 58: 295–300.
23 NCBI Resource Coordinators. Database resources of the National
Center for Biotechnology Information. Nucleic Acids Res 2013;
41: D8–20.
24 Degenhardt L, Whiteford HA, Ferrari AJ, Baxter A, Charlson FJ,
Hall W. Global burden of disease attributable to illicit drug use and
dependence: findings from the Global Burden of Disease study 2010.
Lancet 2013; 382: 1564–74.
25 Institute for Health Metrics and Evaluation. Global Burden of
Disease Study 2015 (GBD 2015) Socio-Demographic Index (SDI)
1980–2015. http://ghdx.healthdata.org/record/global-burden-
disease-study-2015-gbd-2015-socio-demographic-index-sdi-
1980%E2%80%932015 (accessed May 16, 2018).
26 Gmel G, Gutjahr E, Rehm J. How stable is the risk curve between
alcohol and all-cause mortality and what factors influence the
shape? A precision-weighted hierarchical meta-analysis.
Eur J Epidemiol 2003; 18: 631–42.
27 Holman CD, English DR, Milne E, Winter MG. Meta-analysis of
alcohol and all-cause mortality: a validation of NHMRC
recommendations. Med J Aust 1996; 164: 141–45.
28 Stockwell T, Zhao J, Panwar S, Roemer A, Naimi T, Chikritzhs T.
Do ‘moderate’ drinkers have reduced mortality risk? A systematic
review and meta-analysis of alcohol consumption and all-cause
mortality. J Stud Alcohol Drugs 2016; 77: 185–98.
29 WHO. Tackling NCDs: ‘best buys’ and other recommended
interventions for the prevention and control of noncommunicable
diseases. Geneva: World Health Organization, 2017.
30 Karriker-Jae KJ, Room R, Giesbrecht N, Greenfield TK.
Alcohol’s harm to others: opportunities and challenges in a public
health framework. J Stud Alcohol Drugs 2018; 79: 239–43.
31 Holst C, Tolstrup JS, Sørensen HJ, Becker U. Alcohol dependence
and risk of somatic diseases and mortality: a cohort study in
19 002 men and women attending alcohol treatment. Addiction 2017;
112: 1358–66.
32 Topiwala A, Ebmeier KP. Eects of drinking on late-life brain and
cognition. Evid-Based Ment Health 2018; 21: 12–15.
33 Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J, for
the QalyDays Study Group. Contribution of alcohol use disorders to
the burden of dementia in France 2008–13: a nationwide
retrospective cohort study. Lancet Public Health 2018; 3: e124–32.
... Noncommunicable diseases are the reason for 74% of all deaths globally, and risky health behaviours are the primary modifiable risk factors for them [1,2]. risky health behaviours are actions taken by individuals that affect their health in a harmful way [3]. ...
... beyond recommended limits of 8 portions per week for women and 15 for men [4]), and physical inactivity (usually defined as not achieving physical activity guidelines [5]. these three risky behaviours are well-known risk factors for multiple diseases, functional impairments, and premature death [1]. ...
... For example, health education became an independent school subject in Finland in 2004 [71] and current young adults have received more structured health education than previous cohorts. While smoking is the only risky health behaviour showing a globally decreasing trend due to changes in attitudes and restrictions [1], the use of other drugs (e.g. cannabis) has increased [72]. ...
Article
Full-text available
Background Both the number of risky health behaviours and the duration of exposure to these behaviours over time may increase the risk of later adverse outcomes. This study examined cumulative associations of risky health behaviours with both positive and negative aspects of mental well-being and health. It has a uniquely long follow-up period of over 30 years, from early adulthood to the beginning of late adulthood. Materials and methods The data were from the Jyväskylä Longitudinal Study of Personality and Social Development. The participants represent the Finnish age cohort born in 1959. This study utilized data collected at ages 27 (1986), 36 (1995), 42 (2001), 50 (2009), and 61 (2020–2021) (n = 206–326). Risk scores indicating the current number of risky behaviours of smoking, heavy alcohol consumption, and physical inactivity and their temporal accumulation over time were calculated. The associations of risk scores with mental well-being (depressive symptoms, psychological well-being) and health (self-rated health, number of metabolic risk factors) from age 36 onwards were analyzed with linear multilevel models adjusted for gender and education. Results More current risky behaviours were associated with more depressive symptoms (B = 0.10, p = 0.032), lower psychological well-being (B = -0.10, p = 0.010), lower self-rated health (B = -0.45, p < 0.001), and more metabolic risk factors (B = 0.53, p = 0.013). The associations of temporal risk scores with the outcomes were even stronger (depressive symptoms: B = 0.38, p < 0.001; psychological well-being: B = -0.15, p = 0.046; self-rated health: B = -0.82, p < 0.001; metabolic risk factors: B = 1.49, p < 0.001). Among individual behaviours, the temporal risk score of alcohol consumption was negatively associated with most outcomes, while smoking was associated with poorer mental well-being and physical inactivity with poorer health. Conclusions The current and temporal accumulation of multiple risky health behaviours were associated with poorer mental well-being and health. Preventing these behaviours early in adulthood and midlife is crucial to avoid their accumulation and subsequent health risks.
... However, over the following 20 years the earlier evidence for possible health benefits of moderate alcohol consumption has been challenged [25][26][27], and put into a more realistic perspective in terms of population impact [28]. Awareness has grown of evidence that increased risk of breast cancer begins at low levels of consumption, often referred to as 'no safe level' [29]. ...
Article
Full-text available
Background Alcohol is a global health issue with a high level of controversy. After being absent from World Health Organization (WHO) global governing body discussions for about 20 years, alcohol re-entered the agenda in 2005. The expression ‘harmful use of alcohol’ became the compromise language after hard negotiations, an example of ‘adopted language” that has remained for almost 20 years. This article analyses the background and use of the expression 'harmful use of alcohol' in the context of WHO governing bodies, current challenges and implications for public health. Methods The article is based on textual analysis of source documents from the time periods 2004–2010 and 2019–2022 and the authors’ experience from involvement in the global alcohol policy scene for more than 20 years: WHO governing body records and other documents were analysed, as well as Member State and Non-State Actors’ positions and contributions in consultations and statements in WHO governing body debates. Results The introduction of the concept ‘harmful use of alcohol’ in WHO documents from 2005 onwards was a political compromise between approaches focussed either on ‘alcohol abuse’ or a wider concept of harm from alcohol consumption. It has permeated into national alcohol policy documents, academic literature about alcohol harm and UN documents, and been embraced by the alcohol industry. However, it has not prevented and some would argue that it has enabled development of normative statements from WHO that include recommendations for population wide interventions. The relatively new evidence of harm from alcohol at low levels and questioning of evidence suggesting a beneficial effect of moderate use of alcohol together with industry appropriation of 'harmful use' have led to increasing critique of the framing implied by ‘harmful use of alcohol’. Conclusions The language used in WHO documents holds political power in that it may influence the subsequent course of events. This is accentuated by the normative role of WHO in global health policy and the uptake of negotiated language beyond WHO documents. In the next five years it will be possible and valuable to examine in more detail the extent to which this power was made manifest and the need and possible ways to effect change.
... The risk of alcohol-related diseases increases with increasing levels of alcohol consumption, and the level of consumption that minimizes this risk is zero. 20 It is important for interventions to reach all alcohol users, considering the health burden related to alcohol consumption among the total population. If the intervention approach in this study proves to be sufficiently effective, our findings will support the implementation of SBI in the daily practice by more occupational health workers. ...
Article
Background Despite evidence regarding the effectiveness of screening and brief interventions for excessive alcohol consumption, these interventions are not widely used. Although several studies have suggested that face-to-face interventions in the workplace may be effective, developing an implementable intervention strategy for alcohol users, including light drinkers, is warranted. This study aimed to develop a study protocol to evaluate the effect of providing an educational leaflet at the workplace on reducing hazardous or harmful alcohol use. Methods A randomized controlled trial involving employees (aged ≥ 20 years) of a local administrative office in Japan who were screened using the Alcohol Use Disorder Identification Test (AUDIT) is ongoing. Participants were randomized into “Educational leaflet” and “Control (no intervention)” groups. The primary outcome was the difference in negative status on the AUDIT (proportion of participants scoring < 8 points on the AUDIT) between the intervention and control groups in the following year. For the secondary outcomes, laboratory marker data at annual health checkups were collected and assessed. Results A total of 400 participants were randomized into educational leaflet (n = 200) and control (n = 200) groups. The basic characteristics of all participants included sex (men 79.3%; women 20.8%), mean (standard deviation) of age 48.5 (9.7 years), 40.0% of AUDIT ≥ 8 points, 46.8% of drinking alcohol ≥ 4 times a week, and 33.8% of heavy episodic drinking. No significant differences were observed between the intervention and control groups in terms of the baseline variables. Conclusions This study protocol developed the first trial in Japan to investigate the impact of providing an educational leaflet after screening for hazardous and harmful alcohol use in a workplace setting. The findings of this study can provide the first evidence that an implementable alcohol intervention strategy targeting alcohol users, including light drinkers in the workplace, is effective in reducing hazardous or harmful alcohol use.
... In contrast, alcohol consumption among females was 8.9% and among males was 20% in low and middle-income IJMRA, Volume 8 Issue 04 April 2025 www.ijmra.in Page 1738 countries (LMICs) [1][2][3] . In 2019, approximately 2.4 million deaths were attributed to alcohol consumption, accounting for 4.3% of all deaths globally. ...
Article
Alcohol consumption is a recognized risk factor for cardiovascular diseases, including hypertension. However, its specific effects on carotid vessels have not been extensively studied. Understanding these effects is crucial for gaining insights into the pathogenesis of cardiovascular diseases, particularly in regions with high alcohol consumption like Nigeria. Methods A cross-sectional study, conducted in Rumuekini, Nigeria, involving forty-seven male (mean age 34.49 ± 17.25 years). Participants were categorized into mild, moderate, and excessive drinkers of alcohol. Data on blood pressures, body mass index, and carotid artery parameters were collected. Statistical analysis was performed to compare these parameters between alcohol consumers and data from control group of non-consumers. Results The mean SBP and DBP for alcohol consumers were 128.10 ± 21.92 mmHg and 77.20 ± 14.87 mmHg. The average daily alcohol consumption was 74.24 ± 43.34 g/day. BMI was significantly lower in alcohol consumers (23.46 ± 2.82 kg/m²) compared to nonconsumers (p=0.014). Right carotid diameter was also significantly smaller in alcohol consumers (p=0.027). The analysis indicated that even mild alcohol consumption was associated with elevated blood pressure. Additionally, BMI across all alcohol consumption levels fell within the overweight range, highlighting potential weight-related health issues. Conclusion Excessive Alcohol consumption, is associated with elevated blood pressures and increased cardiovascular risks. Alcohol consumers exhibit a smaller right carotid diameter, indicating potential vascular narrowing. These changes suggest that alcohol impacts blood vessels differently from non-consumers, contributing to increased risk of atherosclerosis and cardiovascular diseases, highlighting the need for targeted public health interventions.
... Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) are the leading causes of the burden of liver disease globally [1,2]. Both conditions also represent the most frequent causes of steatotic liver disease (SLD) in contrast to other etiologies, such as hepatitis C virus (HCV) chronic infection, Wilson's disease and rare monogenic diseases [3]. ...
Article
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease (ALD) are the major contributors to the liver disease burden globally. The rise in these conditions is linked to obesity, type 2 diabetes, metabolic syndrome and increased alcohol consumption. MASLD and ALD share risk factors, pathophysiology and histological features but differ in their thresholds for alcohol use, and the ALD definition does not require the presence of metabolic dysfunction. A recent multi‐society consensus overhauled the nomenclature of liver steatosis and introduced the term MetALD to describe patients with metabolic dysfunction who drink more than those with MASLD and less than those with ALD. This new terminology aims to enhance the understanding and management of liver disease but poses challenges, such as the need to accurately measure alcohol consumption in research and clinical practice settings. Recent studies show that MetALD has significant implications for patient management, as it is associated with increased mortality risks and more severe liver outcomes compared to MASLD alone. MetALD patients face increased risks of liver disease progression, cancer and cardiovascular disease. The diagnosis of MetALD involves the adequate quantification of alcohol use through standardised questionnaires and/or biomarkers as well as proper assessment of liver disease stage and progression risk using non‐invasive tools including serologic markers, imaging, elastography techniques and genetic testing. Effective management requires addressing both metabolic and alcohol‐related factors to improve outcomes. This review intends to provide a comprehensive overview of MetALD, covering pathogenesis, potential diagnostic approaches, management strategies and emerging therapies.
Article
Full-text available
España se ha considerado una de las regiones de referencia de la Dieta Mediterránea, conocida por su contribución a la mejora en la calidad de vida. Esta dieta se caracteriza por el consumo de aceite de oliva, productos frescos, vino tinto, más pescado que carne y pocos alimentos procesados. Nuestro objetivo es conocer las pautas de consumo de la población española general y sus distintas regiones, analizando cómo pueden agruparse y su grado de adherencia a la Dieta Mediterránea. A este respecto, además de un análisis descriptivo del consumo de cada región española y de cada grupo de alimentos, se realiza un análisis de conglomerados en dos etapas usando el método jerárquico de Ward y el método de K-medias para clasificar las regiones españolas en base al consumo alimentario. Adicionalmente, se analizará la adherencia de la dieta española a la Dieta Mediterránea. La variable, “patrón de consumo de la Dieta Mediterránea” se compara con las distintas regiones españolas. Es difícil, en virtud de los resultados situar las pautas de consumo actuales en España dentro de los estándares de la Dieta Mediterránea.
Article
Full-text available
Long-term exposure to the fine particulate matter (PM 2.5) is a risk factor for cardiorespiratory mortality. However, little is known about its distribution and health impact in large cities in low-middle-income countries where population exposure has increased during the last decades. This ecological study evaluated the association between PM 2.5 concentration and adult cardiorespi-ratory mortality at the intraurban census sector (CS) level of Colombia's five most populated cities (2015-2019). We estimated incidence rate ratios (IRR; per 5µg/m 3) by fitting negative binomial regressions to smoothed Bayesian mortality rates (BMR) on PM 2.5 predicted from land use regression (LUR) models, adjusting for CS demographic structure, multidimensional poverty index , and spatial autocorrelation. CS median PM 2.5 ranged from 8.1µg/m 3 in Bucaramanga to 18.7µg/m 3 in Medellín, whereas Bogotá had the highest variability (IQR = 29.5µg/m 3) and cardiorespiratory mortality (BMR = 2,560 per 100,000). Long-term exposure to PM 2.5 increased cardiorespiratory mortality in Bucaramanga (IRR = 1.15; 95%CI: 1.02; 1.31), without evidence of spatial clustering, and cardiovascular (IRR = 1.06; 95%CI: 1.01; 1.12) and respiratory (IRR = 1.07; 95%CI: 1.02; 1.13) mortality in Medellín. Cardiorespira-tory mortality spatially clustered in some Colombian cities and was associated with long-term exposure to PM 2.5 in urban areas where the LUR models had the highest predictive accuracy. These findings highlight the need to incorporate high-quality, high-resolution exposure assessments to better understand the health impact of air pollution and inform public health interventions in urban environments.
Preprint
Full-text available
Background: Military populations are known to have higher prevalence and heavier alcohol use compared to the general population globally. This has serious negative implications to the military. The objective of this study was to describe the prevalence, patterns and associated factors of binge drinking among male military personnel in the Sri Lanka Army. Methods: A cross sectional study was conducted among 1337 male army personnel in active service using multistage sampling. A self-administered questionnaire and the interviewer-administered Alcohol Use Disorders Identification Test which is a 10-item screening tool were used. Prevalence of binge drinking was summarised as a proportion with 95% Confidence Intervals (CI). Age specific prevalence rates and the age standardized prevalence rate of binge drinking were calculated. The standard measure of one unit of alcohol being equivalent to 10g of pure alcohol was used as a reference to calculate the units of alcohol consumption.Binary logistic regression analysis was used to determine the factors associated with binge drinking. Results: The overall prevalence of binge drinking was 51.2% (95% CI 48.5%-54.0%). The age standardized prevalence of binge drinking was 28.3%. The majority binge drank once a month (50.4%). Binge drinkers used 5.6 median units of alcohol on a typical day, 84% consumed arrack, 69.3% have ever thought or attempted to quit and median age of first alcohol consumption was 18 years. When controlled for confounding, those who had mental distress (AOR 2.46, 95% CI=1.72-3.53), had sex with a commercial sex worker (AOR 1.92, 95% CI= 1.21-3.06), were ever smokers (AOR 1.69, 95% CI=1.27-2.25), had serious consequences (AOR 1.58, 95% CI= 1.13-2.20), currently used cannabis (AOR 1.39, 95% CI= 1.02-1.89) and had combat exposure (AOR 1.37, 95% CI 1.00-1.87) were associated with a higher likelihood of binge drinking. Conclusions: The high prevalence of binge drinking warrants immediate advocacy to the highest level of command of the Sri Lanka Army for support to implement sustainable evidence-based alcohol prevention programmes.
Article
Full-text available
Drug addiction is a complex issue influenced by biological, psychological, and social factors. Historically, substance use disorders (SUDs) have been studied primarily in men, overlooking crucial gender differences. However, emerging research reveals that women exhibit unique drug use patterns, distinct neurobiological responses, and specific psychosocial challenges in addiction and recovery. Understanding these differences is essential for developing gender-sensitive prevention and treatment approaches. Neurobiologically, sex hormones such as estrogen and progesterone modulate drug sensitivity, leading to a faster progression from initial use to dependence in women. The mesolimbic dopamine system and prefrontal cortex demonstrate sex-specific activity, influencing cravings, reward processing, and relapse vulnerability. Additionally, hormonal fluctuations and stress responses contribute to more severe withdrawal symptoms and increased relapse risk in women. Social and psychological factors further differentiate addiction in women. They are more likely to use substances as a coping mechanism for trauma, anxiety, and depression. Gender roles and societal stigma discourage help-seeking, while caregiving responsibilities, economic dependence, and intimate partner relationships create additional treatment barriers. Women also face heightened risks of substance-related violence and exploitation Despite these challenges, gender-responsive interventions incorporating trauma-informed care, mental health support, and social empowerment strategies have shown promising outcomes. Addressing co-occurring psychiatric disorders and providing childcare support can enhance rehabilitation success. However, addiction research remains predominantly male-focused, necessitating a paradigm shift toward inclusive, gender-sensitive treatment frameworks. This review synthesizes neurobiological, social, and psychological perspectives to guide more effective, tailored interventions for women. Keywords: Gender differences, drug addiction, neurobiology, social factors, psychological perspectives
Article
Glucagon‐like peptide‐1 receptor agonists (GLP1RAs) are used for the management of type 2 diabetes (T2DM) and obesity. GLP1RAs induce significant weight loss but concerns have been raised regarding the associated effects on muscle mass (MM). We therefore conducted a systematic review and meta‐analysis assessing the effects of GLP1RAs on various measures of MM in individuals living with overweight or obesity, with and without T2DM. Comprehensive search of Medline, Pubmed, EMBASE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar was performed. Studies involving cohorts with a mean age over 40 years and a mean body mass index over 25 kg.m ‐2 were included. The primary outcome was any measure used to estimate MM, whilst fat mass (FM) and total body weight were included as secondary outcomes. Thirty‐eight publications, involving 1735 participants, were included in the review. Separate meta‐analyses were performed for studies involving participants with T2DM and individuals without T2DM (non‐DM). In individuals with T2DM, GLP1RAs induced a non‐significant mean reduction in MM measures (‐0.74 kg, 95% CI: ‐1.61, 0.14, p = 0.10), despite significantly reducing FM (‐3.18 kg, 95% CI: ‐4.09, ‐2.28, p < 0.0001). In the non‐DM analysis, a significant mean reduction in MM measures was observed (‐1.41 kg, 95% CI: ‐2.12, ‐0.71, p = 0.0001), however, this was significantly less than the reduction in FM (‐6.02 kg, 95% CI: ‐7.53, ‐4.50, p < 0.0001). In both populations, the reduction in measures of MM accounted for less than 20% of the total weight reduction. These findings provide some clarity to clinicians that use GLP1RAs to manage individuals with T2DM and/or obesity, however, further more detailed analysis of the impact of these medications on functional skeletal muscle is required.
Article
Full-text available
Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease. By providing estimates over a long time series, this study can monitor risk exposure trends critical to health surveillance and inform policy debates on the importance of addressing risks in context. Methods: We used the comparative risk assessment framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2016. This study included 481 risk-outcome pairs that met the GBD study criteria for convincing or probable evidence of causation. We extracted relative risk (RR) and exposure estimates from 22 717 randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources, according to the GBD 2016 source counting methods. Using the counterfactual scenario of theoretical minimum risk exposure level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. Finally, we explored four drivers of trends in attributable burden: population growth, population ageing, trends in risk exposure, and all other factors combined. Findings: Since 1990, exposure increased significantly for 30 risks, did not change significantly for four risks, and decreased significantly for 31 risks. Among risks that are leading causes of burden of disease, child growth failure and household air pollution showed the most significant declines, while metabolic risks, such as body-mass index and high fasting plasma glucose, showed significant increases. In 2016, at Level 3 of the hierarchy, the three leading risk factors in terms of attributable DALYs at the global level for men were smoking (124·1 million DALYs [95% UI 111·2 million to 137·0 million]), high systolic blood pressure (122·2 million DALYs [110·3 million to 133·3 million], and low birthweight and short gestation (83·0 million DALYs [78·3 million to 87·7 million]), and for women, were high systolic blood pressure (89·9 million DALYs [80·9 million to 98·2 million]), high body-mass index (64·8 million DALYs [44·4 million to 87·6 million]), and high fasting plasma glucose (63·8 million DALYs [53·2 million to 76·3 million]). In 2016 in 113 countries, the leading risk factor in terms of attributable DALYs was a metabolic risk factor. Smoking remained among the leading five risk factors for DALYs for 109 countries, while low birthweight and short gestation was the leading risk factor for DALYs in 38 countries, particularly in sub-Saharan Africa and South Asia. In terms of important drivers of change in trends of burden attributable to risk factors, between 2006 and 2016 exposure to risks explains an 9·3% (6·9-11·6) decline in deaths and a 10·8% (8·3-13·1) decrease in DALYs at the global level, while population ageing accounts for 14·9% (12·7-17·5) of deaths and 6·2% (3·9-8·7) of DALYs, and population growth for 12·4% (10·1-14·9) of deaths and 12·4% (10·1-14·9) of DALYs. The largest contribution of trends in risk exposure to disease burden is seen between ages 1 year and 4 years, where a decline of 27·3% (24·9-29·7) of the change in DALYs between 2006 and 2016 can be attributed to declines in exposure to risks. Interpretation: Increasingly detailed understanding of the trends in risk exposure and the RRs for each risk-outcome pair provide insights into both the magnitude of health loss attributable to risks and how modification of risk exposure has contributed to health trends. Metabolic risks warrant particular policy attention, due to their large contribution to global disease burden, increasing trends, and variable patterns across countries at the same level of development. GBD 2016 findings show that, while it has huge potential to improve health, risk modification has played a relatively small part in the past decade. Funding: The Bill & Melinda Gates Foundation, Bloomberg Philanthropies.
Article
The emergent and growing body of research on alcohol's harm to others (AHTO), or secondhand effects of drinking, has important implications for prevention, intervention, and policy. Those victimized by other drinkers tend to favor effective alcohol policies more than their nonvictimized peers, but often a community's impulse will be to combat AHTO by targeting and stigmatizing individual heavy drinkers, rather than taking a public health approach to reducing harm. Here we discuss opportunities and challenges in selecting ways of reducing AHTO. We make a case for adopting joint public health and individual approaches to reduce AHTO.
Article
Background: Dementia is a prevalent condition, affecting 5–7% of people aged 60 years and older, and a leading cause of disability in people aged 60 years and older globally. We aimed to examine the association between alcohol use disorders and dementia risk, with an emphasis on early-onset dementia (1·7) in sensitivity analyses on dementia case definition (including Alzheimer's disease) or older study populations. Also, alcohol use disorders were significantly associated with all other risk factors for dementia onset (all p
Article
The National Center for Biotechnology Information (NCBI) provides a large suite of online resources for biological information and data, including the GenBank ® nucleic acid sequence database and the PubMed database of citations and abstracts for published life science journals. The Entrez system provides search and retrieval operations for most of these data from 39 distinct databases. The E-utilities serve as the programming interface for the Entrez system. Augmenting many of the Web applications are custom implementations of the BLAST program optimized to search specialized data sets. New resources released in the past year include PubMed Data Management, RefSeq Functional Elements, genome data download, variation services API, Magic-BLAST, QuickBLASTp, and Identical Protein Groups. Resources that were updated in the past year include the genome data viewer, a human genome resources page, Gene, virus variation, OSIRIS, and PubChem. All of these resources can be accessed through the NCBI home page at www.ncbi.nlm.nih.gov. © Published by Oxford University Press on behalf of Nucleic Acids Research 2017.
Article
Alcohol consumption is common in Western countries and has been increasing in older adults. Latest figures from Great Britain suggest 75% of those over 65 years drink, an increase from 71% 10 years ago. Chronic heavy intake is a well-established cause of brain atrophy and dementia, with a recent long-term prospective study from the USA reporting a doubling of the odds of later severe memory impairment in those with a history of an alcohol use disorder. Drinking of moderate amounts has been reported to be protective for brain health in a number of epidemiological studies, including some claims of possibly reducing dementia risk. Rigorous recent research has questioned this belief, with new evidence of harmful associations in moderate drinkers compared with abstainers. This has raised suspicion that reported protective effects of moderate drinking were due to confounding by socioeconomic class and intelligence. Clinicians should look out for cognitive impairment in heavy drinkers, considering that abstinence may induce a degree of clinical improvement. Discussions with patients regarding moderate drinking should be informed by recent research. Health benefits of moderate drinking at least for cognitive function are questionable, and if they exist are probably limited to one unit of alcohol daily with respect to other body systems.
Article
Aims: To (1) estimate sex-specific risks of a comprehensive spectrum of somatic diseases in alcohol dependent individuals versus a control population, and in the same population to (2) estimate sex-specific risks of dying from the examined somatic diseases. Design: Register-based matched cohort study. Alcohol dependent individuals were identified from an alcohol treatment database. Controls were randomly selected from the Danish Civil Registration System. Information on somatic diseases obtained from the Danish National Patient Registry and causes of death obtained from the Cause of Death Registry. Cox proportional hazards model was applied to estimate Hazard ratios (HRs). Setting: Denmark. Participants: 19,002 alcohol dependent individuals and 186,767 controls. Measurements: Outcome variables included 11 disease groups and 29 sub-groups, defined according to the International Classification of Diseases (ICD). The main predictor variable was diagnosis of alcohol dependence according to ICD. Findings: Alcohol dependent men and women compared with controls had statistically significantly higher risks of all disease groups and the majority of sub-groups when analysed as disease events. HRs were elevated for well-established alcohol-related diseases but also for diseases such as dementia (Men, HR: 2.0; 95% CI: 1.6-2.3. Women, HR: 2.4; 95% CI: 1.8-3.2), psoriasis (Men, HR: 4.3; 95% CI: 3.5-5.2. Women, HR: 5.4; 95% CI: 3.7-7.8) and breast cancer in men (HR: 3.3; 95% CI: 1.6-7.0). Similar results were found when disease groups and sub-groups were analysed as causes of death. Conclusions: Alcohol dependent men and women have significantly higher risks of a comprehensive spectrum of somatic diseases, both as disease events and as causes of death, relative to individuals from the general population.